Journal Article
. 2014 Nov; 515(7528):568-71.
doi: 10.1038/nature13954.

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C Tumeh 1 Christina L Harview 2 Jennifer H Yearley 3 I Peter Shintaku 2 Emma J M Taylor 2 Lidia Robert 2 Bartosz Chmielowski 1 Marko Spasic 2 Gina Henry 2 Voicu Ciobanu 2 Alisha N West 2 Manuel Carmona 2 Christine Kivork 2 Elizabeth Seja 2 Grace Cherry 2 Antonio J Gutierrez 2 Tristan R Grogan 2 Christine Mateus 4 Gorana Tomasic 4 John A Glaspy 1 Ryan O Emerson 5 Harlan Robins 6 Robert H Pierce 3 David A Elashoff 1 Caroline Robert 4 Antoni Ribas 1 
  • PMID: 25428505
  •     19 References
  •     2552 citations


Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8(+) T cells (termed adaptive immune resistance). Here we show that pre-existing CD8(+) T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8(+) T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8(+) T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Stefani Spranger, Robbert M Spaapen, +4 authors, Thomas F Gajewski.
Sci Transl Med, 2013 Aug 30; 5(200). PMID: 23986400    Free PMC article.
Highly Cited.
Using synthetic templates to design an unbiased multiplex PCR assay.
Christopher S Carlson, Ryan O Emerson, +11 authors, Harlan Robins.
Nat Commun, 2013 Oct 26; 4. PMID: 24157944
Highly Cited.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response.
Jaikumar Duraiswamy, Gordon J Freeman, George Coukos.
Cancer Res, 2014 Jan 11; 74(2). PMID: 24408920
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.
Tobias Bald, Jennifer Landsberg, +11 authors, Thomas Tüting.
Cancer Discov, 2014 Mar 05; 4(6). PMID: 24589924
Highly Cited.
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Mohammad Atefi, Earl Avramis, +9 authors, Antoni Ribas.
Clin Cancer Res, 2014 May 09; 20(13). PMID: 24812408    Free PMC article.
Highly Cited.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
Caroline Robert, Antoni Ribas, +22 authors, Adil Daud.
Lancet, 2014 Jul 19; 384(9948). PMID: 25034862
Highly Cited.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, +7 authors, Robert A Anders.
Clin Cancer Res, 2014 Apr 10; 20(19). PMID: 24714771    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.
Harlan S Robins, Paulo V Campregher, +6 authors, Christopher S Carlson.
Blood, 2009 Aug 27; 114(19). PMID: 19706884    Free PMC article.
Highly Cited.
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
Andrew T Parsa, James S Waldron, +10 authors, Russell O Pieper.
Nat Med, 2006 Dec 13; 13(1). PMID: 17159987
Highly Cited.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, +13 authors, Franck Pagès.
Science, 2006 Sep 30; 313(5795). PMID: 17008531
Highly Cited.
Effector memory T cells, early metastasis, and survival in colorectal cancer.
Franck Pagès, Anne Berger, +13 authors, Jérôme Galon.
N Engl J Med, 2005 Dec 24; 353(25). PMID: 16371631
Highly Cited.
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, +9 authors, George Coukos.
N Engl J Med, 2003 Jan 17; 348(3). PMID: 12529460
Highly Cited.
Cancer: Antitumour immunity gets a boost.
Jedd D Wolchok, Timothy A Chan.
Nature, 2014 Nov 28; 515(7528). PMID: 25428495    Free PMC article.
Tumour immunology: Checkpoint parley.
Yvonne Bordon.
Nat Rev Immunol, 2014 Dec 06; 15(1). PMID: 25475446
Immunotherapy: Checkpoint parley.
Yvonne Bordon.
Nat Rev Cancer, 2014 Dec 17; 15(1). PMID: 25503072
Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer.
Alessia Errico.
Nat Rev Clin Oncol, 2014 Dec 24; 12(2). PMID: 25533942
Clinical blockade of PD1 and LAG3--potential mechanisms of action.
Linh T Nguyen, Pamela S Ohashi.
Nat Rev Immunol, 2014 Dec 24; 15(1). PMID: 25534622
Highly Cited. Review.
Classification of current anticancer immunotherapies.
Lorenzo Galluzzi, Erika Vacchelli, +85 authors, Guido Kroemer.
Oncotarget, 2014 Dec 30; 5(24). PMID: 25537519    Free PMC article.
Highly Cited. Review.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
Objective measurement and clinical significance of TILs in non-small cell lung cancer.
Kurt A Schalper, Jason Brown, +5 authors, David L Rimm.
J Natl Cancer Inst, 2015 Feb 05; 107(3). PMID: 25650315    Free PMC article.
Highly Cited.
Prognostic and predictive value of PDL1 expression in breast cancer.
Renaud Sabatier, Pascal Finetti, +7 authors, François Bertucci.
Oncotarget, 2015 Feb 12; 6(7). PMID: 25669979    Free PMC article.
Highly Cited.
Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy.
Tri Giang Phan, Georgina V Long, Richard A Scolyer.
Immunol Cell Biol, 2015 Feb 18; 93(4). PMID: 25686808
Immunotherapeutic advancements for glioblastoma.
Leonel Ampie, Eric C Woolf, Christopher Dardis.
Front Oncol, 2015 Feb 18; 5. PMID: 25688335    Free PMC article.
Tryptophan-degrading enzymes in tumoral immune resistance.
Nicolas van Baren, Benoît J Van den Eynde.
Front Immunol, 2015 Feb 19; 6. PMID: 25691885    Free PMC article.
Highly Cited. Review.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Naiyer A Rizvi, Julien Mazières, +27 authors, Suresh S Ramalingam.
Lancet Oncol, 2015 Feb 24; 16(3). PMID: 25704439    Free PMC article.
Highly Cited.
Biomarkers for glioma immunotherapy: the next generation.
Jennifer S Sims, Timothy H Ung, +2 authors, Jeffrey N Bruce.
J Neurooncol, 2015 Mar 01; 123(3). PMID: 25724916    Free PMC article.
Targeting cancer-specific mutations by T cell receptor gene therapy.
Thomas Blankenstein, Matthias Leisegang, Wolfgang Uckert, Hans Schreiber.
Curr Opin Immunol, 2015 Mar 03; 33. PMID: 25728991    Free PMC article.
The STING pathway and the T cell-inflamed tumor microenvironment.
Seng-Ryong Woo, Leticia Corrales, Thomas F Gajewski.
Trends Immunol, 2015 Mar 12; 36(4). PMID: 25758021    Free PMC article.
Highly Cited. Review.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.
B Paiva, A Azpilikueta, +13 authors, I Melero.
Leukemia, 2015 Mar 18; 29(10). PMID: 25778100
Highly Cited.
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Harriet M Kluger, Christopher R Zito, +6 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2015 Mar 20; 21(13). PMID: 25788491    Free PMC article.
Highly Cited.
Overcoming T cell exhaustion in infection and cancer.
Kristen E Pauken, E John Wherry.
Trends Immunol, 2015 Mar 24; 36(4). PMID: 25797516    Free PMC article.
Highly Cited. Review.
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Katy K Tsai, Adil I Daud.
Drugs, 2015 Mar 25; 75(6). PMID: 25802230
Intravital and whole-organ imaging reveals capture of melanoma-derived antigen by lymph node subcapsular macrophages leading to widespread deposition on follicular dendritic cells.
Federica Moalli, Steven T Proulx, +3 authors, Jens V Stein.
Front Immunol, 2015 Mar 31; 6. PMID: 25821451    Free PMC article.
ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy.
Chunyang Li, Weiyun Li, +9 authors, Hongyan Wang.
EMBO Mol Med, 2015 Apr 09; 7(6). PMID: 25851535    Free PMC article.
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
B Homet Moreno, A Ribas.
Br J Cancer, 2015 Apr 10; 112(9). PMID: 25856776    Free PMC article.
Highly Cited. Review.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Macrophages and therapeutic resistance in cancer.
Brian Ruffell, Lisa M Coussens.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858805    Free PMC article.
Highly Cited. Review.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy.
Robert D Leone, Maureen R Horton, Jonathan D Powell.
Cancer Cell, 2015 Apr 16; 27(4). PMID: 25873169    Free PMC article.
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
Inge C van Gool, Florine A Eggink, +14 authors, David N Church.
Clin Cancer Res, 2015 Apr 17; 21(14). PMID: 25878334    Free PMC article.
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
microRNA-4717 differentially interacts with its polymorphic target in the PD1 3' untranslated region: A mechanism for regulating PD-1 expression and function in HBV-associated liver diseases.
Guoyu Zhang, Na Li, +7 authors, Zhengwen Liu.
Oncotarget, 2015 Apr 22; 6(22). PMID: 25895129    Free PMC article.
The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors.
Emanuela Romano, Pedro Romero.
J Immunother Cancer, 2015 Apr 23; 3. PMID: 25901287    Free PMC article.
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Sebastian Kreiter, Mathias Vormehr, +12 authors, Ugur Sahin.
Nature, 2015 Apr 23; 520(7549). PMID: 25901682    Free PMC article.
Highly Cited.
In vivo RNAi screens: concepts and applications.
Shane Crotty, Matthew E Pipkin.
Trends Immunol, 2015 May 06; 36(5). PMID: 25937561    Free PMC article.
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
François Bertucci, Pascal Finetti, +6 authors, Steven van Laere.
Oncotarget, 2015 May 06; 6(15). PMID: 25940795    Free PMC article.
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Janis M Taube, Geoffrey D Young, +10 authors, Suzanne L Topalian.
Clin Cancer Res, 2015 May 07; 21(17). PMID: 25944800    Free PMC article.
Highly Cited.
Combinatorial strategies for the induction of immunogenic cell death.
Lucillia Bezu, Ligia C Gomes-de-Silva, +6 authors, Guido Kroemer.
Front Immunol, 2015 May 13; 6. PMID: 25964783    Free PMC article.
Highly Cited. Review.
Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.
B S Sundarasetty, L Chan, +16 authors, R Stripecke.
Gene Ther, 2015 May 13; 22(9). PMID: 25965393    Free PMC article.
Special Conference on Tumor Immunology and Immunotherapy: A New Chapter.
Katelyn T Byrne, Robert H Vonderheide, Elizabeth M Jaffee, Todd D Armstrong.
Cancer Immunol Res, 2015 May 15; 3(6). PMID: 25968457    Free PMC article.
Immunotherapeutic approaches to sarcoma.
Melissa Burgess, Hussein Tawbi.
Curr Treat Options Oncol, 2015 May 16; 16(6). PMID: 25975445
Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth.
Cancer Res, 2015 May 16; 75(11). PMID: 25977340    Free PMC article.
Highly Cited. Review.
NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.
Frederick J Kohlhapp, Joseph R Broucek, +16 authors, Howard L Kaufman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992289    Free PMC article.
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Xian-De Liu, Anh Hoang, +20 authors, Eric Jonasch.
Cancer Immunol Res, 2015 May 28; 3(9). PMID: 26014097    Free PMC article.
PD-1/PD-L1 inhibitors.
Joel Sunshine, Janis M Taube.
Curr Opin Pharmacol, 2015 Jun 07; 23. PMID: 26047524    Free PMC article.
Highly Cited. Review.
CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
Qing Wang, David J Klinke, Zhijun Wang.
BMC Syst Biol, 2015 Jun 07; 9. PMID: 26048402    Free PMC article.
In-situ tumor vaccination: Bringing the fight to the tumor.
Robert H Pierce, Jean S Campbell, +2 authors, Holbrook E K Kohrt.
Hum Vaccin Immunother, 2015 Jun 10; 11(8). PMID: 26055074    Free PMC article.
Development of individualized anti-metastasis strategies by engineering nanomedicines.
Qianjun He, Shengrong Guo, Zhiyong Qian, Xiaoyuan Chen.
Chem Soc Rev, 2015 Jun 10; 44(17). PMID: 26056688    Free PMC article.
The immune response in cancer: from immunology to pathology to immunotherapy.
Nicolas A Giraldo, Etienne Becht, +2 authors, Wolf H Fridman.
Virchows Arch, 2015 Jun 17; 467(2). PMID: 26077464
Spotlight on pembrolizumab in the treatment of advanced melanoma.
Thanashan Rajakulendran, David N Adam.
Drug Des Devel Ther, 2015 Jun 18; 9. PMID: 26082618    Free PMC article.
Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study.
David J Klinke.
J Immunother Cancer, 2015 Jun 18; 3. PMID: 26082838    Free PMC article.
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Luisa Carbognin, Sara Pilotto, +11 authors, Giampaolo Tortora.
PLoS One, 2015 Jun 19; 10(6). PMID: 26086854    Free PMC article.
Highly Cited.
Genomic Classification of Cutaneous Melanoma.
Cancer Genome Atlas Network.
Cell, 2015 Jun 20; 161(7). PMID: 26091043    Free PMC article.
Highly Cited.
JITC launches a new section: commentary and editorials.
Christian M Capitini, Pedro Romero.
J Immunother Cancer, 2015 Jun 26; 3. PMID: 26110058    Free PMC article.
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
Norman Woller, Engin Gürlevik, +9 authors, Florian Kühnel.
Mol Ther, 2015 Jun 27; 23(10). PMID: 26112079    Free PMC article.
Highly Cited.
Immune monitoring technology primer: immunosequencing.
Ilan Kirsch.
J Immunother Cancer, 2015 Jun 27; 3. PMID: 26113978    Free PMC article.
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Pin Wu, Dang Wu, +2 authors, Jian Huang.
PLoS One, 2015 Jun 27; 10(6). PMID: 26114883    Free PMC article.
Highly Cited. Systematic Review.
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Pablo Penaloza-MacMaster, Nicholas M Provine, Eryn Blass, Dan H Barouch.
J Immunol, 2015 Jun 28; 195(3). PMID: 26116499    Free PMC article.
The emerging role of resident memory T cells in protective immunity and inflammatory disease.
Chang Ook Park, Thomas S Kupper.
Nat Med, 2015 Jun 30; 21(7). PMID: 26121195    Free PMC article.
Highly Cited. Review.
Predictive biomarkers in precision medicine and drug development against lung cancer.
Bingliang Fang, Reza J Mehran, John V Heymach, Stephen G Swisher.
Chin J Cancer, 2015 Jul 03; 34(7). PMID: 26134262    Free PMC article.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Aitziber Buqué, Norma Bloy, +12 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137403    Free PMC article.
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.
L Vassilev, T Ranki, +22 authors, S Pesonen.
Oncoimmunology, 2015 Jul 04; 4(7). PMID: 26140248    Free PMC article.
Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.
Nathalie Vigneron, Nicolas van Baren, Benoît J Van den Eynde.
Oncoimmunology, 2015 Jul 15; 4(5). PMID: 26155395    Free PMC article.
Deciphering the genetic evolution of T-cell resistance in melanoma.
Antje Sucker, Annette Paschen.
Oncoimmunology, 2015 Jul 15; 4(5). PMID: 26155406    Free PMC article.
New immunotherapies targeting the PD-1 pathway.
Jordan M Chinai, Murali Janakiram, +3 authors, Xingxing Zang.
Trends Pharmacol Sci, 2015 Jul 15; 36(9). PMID: 26162965    Free PMC article.
Inhibitory Receptors Beyond T Cell Exhaustion.
Silvia A Fuertes Marraco, Natalie J Neubert, Grégory Verdeil, Daniel E Speiser.
Front Immunol, 2015 Jul 15; 6. PMID: 26167163    Free PMC article.
Highly Cited. Review.
Tumor immune microenvironment characterization and response to anti-PD-1 therapy.
Mariacarmela Santarpia, Niki Karachaliou.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175922    Free PMC article.
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints.
Niki Karachaliou, Maria Gonzalez Cao, +4 authors, Rafael Rosell.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175923    Free PMC article.
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Cristina Teixidó, Niki Karachaliou, +2 authors, Rafael Rosell.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175924    Free PMC article.
Precision medicine for metastatic breast cancer--limitations and solutions.
Monica Arnedos, Cecile Vicier, +4 authors, Fabrice Andre.
Nat Rev Clin Oncol, 2015 Jul 22; 12(12). PMID: 26196250
Highly Cited. Review.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.
J David Peske, Amber B Woods, Victor H Engelhard.
Adv Cancer Res, 2015 Jul 29; 128. PMID: 26216636    Free PMC article.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
From mice to humans: developments in cancer immunoediting.
Michele W L Teng, Jerome Galon, Wolf-Herman Fridman, Mark J Smyth.
J Clin Invest, 2015 Aug 05; 125(9). PMID: 26241053    Free PMC article.
Highly Cited. Review.
Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response.
Martin C Mihm, James J Mulé.
Cancer Immunol Res, 2015 Aug 06; 3(8). PMID: 26242760    Free PMC article.
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Abdullah Alsuliman, Dilek Colak, +5 authors, Hazem Ghebeh.
Mol Cancer, 2015 Aug 08; 14. PMID: 26245467    Free PMC article.
Highly Cited.
Genomic spectra of biliary tract cancer.
Hiromi Nakamura, Yasuhito Arai, +14 authors, Tatsuhiro Shibata.
Nat Genet, 2015 Aug 11; 47(9). PMID: 26258846
Highly Cited.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.
Antoni Ribas.
Cancer Discov, 2015 Aug 15; 5(9). PMID: 26272491    Free PMC article.
Highly Cited. Review.
Leila Khoja, Marcus O Butler, +2 authors, Anthony M Joshua.
J Immunother Cancer, 2015 Aug 20; 3. PMID: 26288737    Free PMC article.
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Xinbing Sui, Junhong Ma, +5 authors, Li Zhang.
Oncotarget, 2015 Aug 26; 6(23). PMID: 26305724    Free PMC article.
Anti program death-1/anti program death-ligand 1 in digestive cancers.
Eléonore de Guillebon, Pauline Roussille, Eric Frouin, David Tougeron.
World J Gastrointest Oncol, 2015 Aug 26; 7(8). PMID: 26306141    Free PMC article.
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
Erica N Bozeman, Sara He, Yalda Shafizadeh, Periasamy Selvaraj.
Hum Vaccin Immunother, 2015 Aug 27; 12(2). PMID: 26308597    Free PMC article.
Perspectives in the treatment of pancreatic adenocarcinoma.
Angel Cid-Arregui, Victoria Juarez.
World J Gastroenterol, 2015 Aug 27; 21(31). PMID: 26309356    Free PMC article.
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Karishma Rajani, Christopher Parrish, +10 authors, Richard Vile.
Mol Ther, 2015 Aug 28; 24(1). PMID: 26310630    Free PMC article.
Highly Cited.
Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma.
K Oguejiofor, J Hall, +6 authors, C M L West.
Br J Cancer, 2015 Aug 28; 113(6). PMID: 26313665    Free PMC article.
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Evan J Lipson, Patrick M Forde, +3 authors, Suzanne L Topalian.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320063    Free PMC article.
Highly Cited. Review.
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Thomas F Gajewski.
Semin Oncol, 2015 Sep 01; 42(4). PMID: 26320069    Free PMC article.
Highly Cited. Review.
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.
Jeanne Galaine, Christophe Borg, Yann Godet, Olivier Adotévi.
Vaccines (Basel), 2015 Sep 10; 3(3). PMID: 26350591    Free PMC article.
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Sonja Kleffel, Christian Posch, +19 authors, Tobias Schatton.
Cell, 2015 Sep 12; 162(6). PMID: 26359984    Free PMC article.
Highly Cited.
Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.
Matthew A Care, David R Westhead, Reuben M Tooze.
Genome Med, 2015 Sep 13; 7. PMID: 26362649    Free PMC article.
Immunotherapies for bladder cancer: a new hope.
Farhad Fakhrejahani, Yusuke Tomita, +3 authors, Andrea B Apolo.
Curr Opin Urol, 2015 Sep 16; 25(6). PMID: 26372038    Free PMC article.
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
Ahmad A Tarhini, Haris Zahoor, +4 authors, John M Kirkwood.
J Immunother Cancer, 2015 Sep 18; 3. PMID: 26380086    Free PMC article.
Highly Cited.
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion.
Stefani Spranger, Thomas F Gajewski.
J Immunother Cancer, 2015 Sep 18; 3. PMID: 26380088    Free PMC article.
The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance.
Natascha Hermann-Kleiter, Victoria Klepsch, +9 authors, Gottfried Baier.
Cell Rep, 2015 Sep 22; 12(12). PMID: 26387951    Free PMC article.
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.
Tao Dao, Dmitry Pankov, +14 authors, David A Scheinberg.
Nat Biotechnol, 2015 Sep 22; 33(10). PMID: 26389576    Free PMC article.
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
Tsukasa Seya, Hiroaki Shime, +3 authors, Misako Matsumoto.
Cancer Sci, 2015 Sep 24; 106(12). PMID: 26395101    Free PMC article.
New developments in the management of advanced melanoma - role of pembrolizumab.
Giuseppina Improta, Isabella Leone, +3 authors, Filippo Fraggetta.
Onco Targets Ther, 2015 Sep 24; 8. PMID: 26396529    Free PMC article.
The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types.
Peter S Linsley, Damien Chaussabel, Cate Speake.
PLoS One, 2015 Sep 24; 10(9). PMID: 26398410    Free PMC article.
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.
Louisa Mezache, Bernard Paniccia, Angelique Nyinawabera, Gerard J Nuovo.
Mod Pathol, 2015 Sep 26; 28(12). PMID: 26403783
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Hojabr Kakavand, Ricardo E Vilain, +6 authors, Richard A Scolyer.
Mod Pathol, 2015 Sep 26; 28(12). PMID: 26403784
T-cell receptor profiling in cancer.
Ilan Kirsch, Marissa Vignali, Harlan Robins.
Mol Oncol, 2015 Sep 26; 9(10). PMID: 26404496    Free PMC article.
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Christina D Pham, Catherine Flores, +10 authors, Duane A Mitchell.
Clin Cancer Res, 2015 Sep 26; 22(3). PMID: 26405194    Free PMC article.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Ahmad A Tarhini, Haris Zahoor, +6 authors, John M Kirkwood.
J Transl Med, 2015 Oct 01; 13. PMID: 26419843    Free PMC article.
Immunotherapy in Sarcoma: Future Horizons.
Melissa Burgess, Vikram Gorantla, Kurt Weiss, Hussein Tawbi.
Curr Oncol Rep, 2015 Oct 02; 17(11). PMID: 26423769
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.
Stuart J Gallagher, Jessamy C Tiffen, Peter Hersey.
Cancers (Basel), 2015 Oct 02; 7(4). PMID: 26426052    Free PMC article.
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, +3 authors, Jeffrey S Weber.
Clin Cancer Res, 2015 Oct 09; 22(4). PMID: 26446948    Free PMC article.
Highly Cited.
Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma.
Sneha Berry, Janis M Taube.
Oncoimmunology, 2015 Oct 10; 4(10). PMID: 26451298    Free PMC article.
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Martha R Neagu, David A Reardon.
Curr Treat Options Oncol, 2015 Oct 12; 16(11). PMID: 26454859
Immunological hallmarks of stromal cells in the tumour microenvironment.
Shannon J Turley, Viviana Cremasco, Jillian L Astarita.
Nat Rev Immunol, 2015 Oct 17; 15(11). PMID: 26471778
Highly Cited. Review.
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
Anna Wilkins, Andrew Furness, +6 authors, Kevin Harrington.
Br J Cancer, 2015 Oct 21; 113(9). PMID: 26484413    Free PMC article.
Immunological landscape and immunotherapy of hepatocellular carcinoma.
Jesús Prieto, Ignacio Melero, Bruno Sangro.
Nat Rev Gastroenterol Hepatol, 2015 Oct 21; 12(12). PMID: 26484443
Highly Cited. Review.
Immune checkpoint inhibitors: a new frontier in bladder cancer.
Max Kates, Nikolai A Sopko, +3 authors, Trinity J Bivalacqua.
World J Urol, 2015 Oct 22; 34(1). PMID: 26487055
Advances in immunotherapy for treatment of lung cancer.
Jean G Bustamante Alvarez, María González-Cao, +4 authors, Rafael Rosell.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487966    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.
Kelly Kersten, Camilla Salvagno, Karin E de Visser.
Front Immunol, 2015 Oct 27; 6. PMID: 26500653    Free PMC article.
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
Zipei Feng, Sachin Puri, +7 authors, Bernard A Fox.
J Immunother Cancer, 2015 Oct 27; 3. PMID: 26500776    Free PMC article.
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Dongjun Peng, Ilona Kryczek, +15 authors, Weiping Zou.
Nature, 2015 Oct 28; 527(7577). PMID: 26503055    Free PMC article.
Highly Cited.
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.
Yiyi Yan, Axel Grothey.
Onco Targets Ther, 2015 Oct 29; 8. PMID: 26508880    Free PMC article.
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Patrick N Harter, Simon Bernatz, +17 authors, Michel Mittelbronn.
Oncotarget, 2015 Oct 31; 6(38). PMID: 26517811    Free PMC article.
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Lijie Zhai, Stefani Spranger, +4 authors, Derek A Wainwright.
Clin Cancer Res, 2015 Nov 01; 21(24). PMID: 26519060    Free PMC article.
Highly Cited. Review.
Novel immunotherapies in lymphoid malignancies.
Connie Lee Batlevi, Eri Matsuki, Renier J Brentjens, Anas Younes.
Nat Rev Clin Oncol, 2015 Nov 04; 13(1). PMID: 26525683    Free PMC article.
Highly Cited. Review.
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Ashley Cimino-Mathews, Elizabeth Thompson, +10 authors, Leisha A Emens.
Hum Pathol, 2015 Nov 04; 47(1). PMID: 26527522    Free PMC article.
Highly Cited.
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.
Stefanie Riesenberg, Angela Groetchen, +15 authors, Michael Hölzel.
Nat Commun, 2015 Nov 05; 6. PMID: 26530832    Free PMC article.
Highly Cited.
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Ayelet Sivan, Leticia Corrales, +9 authors, Thomas F Gajewski.
Science, 2015 Nov 07; 350(6264). PMID: 26541606    Free PMC article.
Highly Cited.
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes.
Martin Lauss, Markus Ringnér, +6 authors, Göran Jönsson.
BMC Med Genomics, 2015 Nov 08; 8. PMID: 26545983    Free PMC article.
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Kathleen M Mahoney, Heather Sun, +8 authors, Gordon J Freeman.
Cancer Immunol Res, 2015 Nov 08; 3(12). PMID: 26546452    Free PMC article.
Highly Cited.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.
Sarah L Scarpace.
Drugs Context, 2015 Nov 18; 4. PMID: 26576187    Free PMC article.
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong.
J Immunol Res, 2015 Nov 19; 2015. PMID: 26579545    Free PMC article.
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Karishma R Rajani, Richard G Vile.
Viruses, 2015 Nov 19; 7(11). PMID: 26580645    Free PMC article.
[Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer].
Zhiyu Huang, Hui Li, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2015 Nov 20; 18(11). PMID: 26582228    Free PMC article.
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.
Theodore S Nowicki, Jennifer L Anderson, Noah Federman.
Pediatr Res, 2015 Nov 26; 79(3). PMID: 26595537
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.
Eric I Marks, Nelson S Yee.
World J Gastrointest Oncol, 2015 Nov 26; 7(11). PMID: 26600933    Free PMC article.
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.
Madhav D Sharma, Rahul Shinde, +12 authors, David H Munn.
Sci Adv, 2015 Nov 26; 1(10). PMID: 26601142    Free PMC article.
Highly Cited.
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Krzysztof M Zak, Radoslaw Kitel, +6 authors, Tad A Holak.
Structure, 2015 Nov 26; 23(12). PMID: 26602187    Free PMC article.
Highly Cited.
Interferons and the Immunogenic Effects of Cancer Therapy.
Andy J Minn.
Trends Immunol, 2015 Nov 26; 36(11). PMID: 26604042    Free PMC article.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ivan Márquez-Rodas, Pablo Cerezuela, +4 authors, Salvador Martín-Algarra.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605313    Free PMC article.
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.
David A Quigley, Vessela Kristensen.
Mol Oncol, 2015 Nov 27; 9(10). PMID: 26607741    Free PMC article.
Overexpression of natural killer group 2 member D ligands predicts favorable prognosis in cholangiocarcinoma.
Mariko Tsukagoshi, Satoshi Wada, +9 authors, Hiroyuki Kuwano.
Cancer Sci, 2015 Nov 27; 107(2). PMID: 26608587    Free PMC article.
Immune suppressive mechanisms in the tumor microenvironment.
David H Munn, Vincenzo Bronte.
Curr Opin Immunol, 2015 Nov 27; 39. PMID: 26609943    Free PMC article.
Highly Cited. Review.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Paolo A Ascierto, Michael Atkins, +34 authors, Magdalena Thurin.
J Transl Med, 2015 Dec 02; 13. PMID: 26619946    Free PMC article.
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, +9 authors, Korinna Jöhrens.
Oncotarget, 2015 Dec 02; 7(2). PMID: 26625204    Free PMC article.
Highly Cited.
Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.
David M Langenau, Alejandro Sweet-Cordero, Robert Wechsler-Reya, Michael A Dyer.
Cancer Res, 2015 Dec 03; 75(24). PMID: 26627009    Free PMC article.
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.
Linda Hammerich, Adam Binder, Joshua D Brody.
Mol Oncol, 2015 Dec 04; 9(10). PMID: 26632446    Free PMC article.
Engineered Materials for Cancer Immunotherapy.
Alexander S Cheung, David J Mooney.
Nano Today, 2015 Dec 08; 10(4). PMID: 26640511    Free PMC article.
IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Grazia Carbotti, Gaia Barisione, +6 authors, Silvano Ferrini.
Oncotarget, 2015 Dec 15; 6(41). PMID: 26657115    Free PMC article.
IL-10: Expanding the Immune Oncology Horizon.
Ivan H Chan, Victoria Wu, +2 authors, John B Mumm.
Receptors Clin Investig, 2015 Dec 15; 2(4). PMID: 26661378    Free PMC article.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, +4 authors, Sherene Loi.
Nat Rev Clin Oncol, 2015 Dec 17; 13(4). PMID: 26667975
Highly Cited. Review.
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.
Diwakar Davar, Mark A Socinski, Sanja Dacic, Timothy F Burns.
Exp Hematol Oncol, 2015 Dec 18; 4. PMID: 26673119    Free PMC article.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Chan-Young Ock, Ah-Rong Nam, +7 authors, Do-Youn Oh.
Gastric Cancer, 2015 Dec 19; 20(1). PMID: 26681196
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.
Clint T Allen, Paul E Clavijo, Carter Van Waes, Zhong Chen.
Cancers (Basel), 2015 Dec 23; 7(4). PMID: 26690220    Free PMC article.
Predictors of clinical response to immunotherapy with or without radiotherapy.
Susan M Hiniker, Holden T Maecker, Susan J Knox.
J Radiat Oncol, 2015 Dec 29; 4. PMID: 26709361    Free PMC article.
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Anna E Vilgelm, C Andrew Johnson, +11 authors, Ann Richmond.
J Natl Cancer Inst, 2016 Jan 01; 108(6). PMID: 26719346    Free PMC article.
Prospects for gene-engineered T cell immunotherapy for solid cancers.
Christopher A Klebanoff, Steven A Rosenberg, Nicholas P Restifo.
Nat Med, 2016 Jan 07; 22(1). PMID: 26735408    Free PMC article.
Highly Cited.
Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis.
Dong-Na Gao, Zhi-Xiang Yang, Qing-Hui Qi.
Int J Clin Exp Med, 2016 Jan 16; 8(10). PMID: 26770525    Free PMC article.
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Zhong-Yi Dong, Si-Pei Wu, +2 authors, Yi-Long Wu.
Tumour Biol, 2016 Jan 19; 37(4). PMID: 26779629
PD-1 Blockade Expands Intratumoral Memory T Cells.
Antoni Ribas, Daniel Sanghoon Shin, +14 authors, Begoña Comin-Anduix.
Cancer Immunol Res, 2016 Jan 21; 4(3). PMID: 26787823    Free PMC article.
Highly Cited.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Sara Pilotto, Luisa Carbognin, +6 authors, Emilio Bria.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798579    Free PMC article.
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
Mariacarmela Santarpia, María González-Cao, +3 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798582    Free PMC article.
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.
Nitin Chakravarti, Victor G Prieto.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798583    Free PMC article.
Shedding light on the molecular determinants of response to anti-PD-1 therapy.
Ross A Soo.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798594    Free PMC article.
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Elizabeth D Thompson, Marianna Zahurak, +9 authors, Ronan J Kelly.
Gut, 2016 Jan 24; 66(5). PMID: 26801886    Free PMC article.
Highly Cited.
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Jennifer N Brudno, Robert P T Somerville, +19 authors, James N Kochenderfer.
J Clin Oncol, 2016 Jan 27; 34(10). PMID: 26811520    Free PMC article.
Highly Cited.
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Katsuhiko Nosho, Yasutaka Sukawa, +11 authors, Yasuhisa Shinomura.
World J Gastroenterol, 2016 Jan 27; 22(2). PMID: 26811607    Free PMC article.
Highly Cited. Review.
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Shu Su, Bian Hu, +13 authors, Baorui Liu.
Sci Rep, 2016 Jan 29; 6. PMID: 26818188    Free PMC article.
Highly Cited.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
A panoply of errors: polymerase proofreading domain mutations in cancer.
Emily Rayner, Inge C van Gool, +4 authors, David N Church.
Nat Rev Cancer, 2016 Jan 30; 16(2). PMID: 26822575
Highly Cited. Review.
Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.
Nicolas Jacquelot, María Paula Roberti, +17 authors, Laurence Zitvogel.
J Invest Dermatol, 2016 Feb 02; 136(5). PMID: 26829031    Free PMC article.
T Cell Vaccinology: Beyond the Reflection of Infectious Responses.
Nathan D Pennock, Justin D Kedl, Ross M Kedl.
Trends Immunol, 2016 Feb 03; 37(3). PMID: 26830540    Free PMC article.
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, +30 authors, Kwok-Kin Wong.
Cancer Res, 2016 Feb 03; 76(5). PMID: 26833127    Free PMC article.
Highly Cited.
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Lee A Wheeler, Andrea G Manzanera, +14 authors, E Antonio Chiocca.
Neuro Oncol, 2016 Feb 05; 18(8). PMID: 26843484    Free PMC article.
Pembrolizumab: A Review in Advanced Melanoma.
Emma D Deeks.
Drugs, 2016 Feb 06; 76(3). PMID: 26846323
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Immunotherapy and Oncogenic Pathways: The PTEN Connection.
Naiyer A Rizvi, Timothy A Chan.
Cancer Discov, 2016 Feb 07; 6(2). PMID: 26851183    Free PMC article.
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
Yanyan Lou, Lixia Diao, +12 authors, Don L Gibbons.
Clin Cancer Res, 2016 Feb 07; 22(14). PMID: 26851185    Free PMC article.
Highly Cited.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan.
Semin Immunol, 2016 Feb 11; 28(1). PMID: 26861544    Free PMC article.
Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.
Francesca M Bosisio, James S Wilmott, +9 authors, Joost J van den Oord.
Mod Pathol, 2016 Feb 13; 29(4). PMID: 26867783
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.
Christina Pfirschke, Camilla Engblom, +18 authors, Mikael J Pittet.
Immunity, 2016 Feb 14; 44(2). PMID: 26872698    Free PMC article.
Highly Cited.
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Jeffrey Weber, Geoffrey Gibney, +11 authors, Yian Ann Chen.
Cancer Immunol Res, 2016 Feb 14; 4(4). PMID: 26873574    Free PMC article.
Highly Cited.
High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.
Zoran Gatalica, Semir Vranic, +2 authors, Sandeep Reddy.
Fam Cancer, 2016 Feb 15; 15(3). PMID: 26875156    Free PMC article.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer.
Lujun Chen, Jun Chen, +8 authors, Jingting Jiang.
Am J Transl Res, 2016 Feb 18; 7(12). PMID: 26885263    Free PMC article.
Multiplexed tissue biomarker imaging.
Edward C Stack, Periklis G Foukas, Peter P Lee.
J Immunother Cancer, 2016 Feb 18; 4. PMID: 26885371    Free PMC article.
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.
Katherine Woods, Ashley J Knights, +4 authors, Jonathan Cebon.
J Immunother Cancer, 2016 Feb 18; 4. PMID: 26885372    Free PMC article.
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.
Lisha Wang, Fei Ren, +7 authors, Liang Cheng.
Mol Diagn Ther, 2016 Feb 20; 20(2). PMID: 26891728
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Chan-Young Ock, Sehui Kim, +12 authors, Dae Seog Heo.
Oncotarget, 2016 Feb 20; 7(13). PMID: 26893364    Free PMC article.
Highly Cited.
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Susan P Foy, Barbara Sennino, +7 authors, Stefanie J Mandl.
PLoS One, 2016 Feb 26; 11(2). PMID: 26910562    Free PMC article.
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Marius Ilie, Véronique Hofman, +2 authors, Paul Hofman.
Virchows Arch, 2016 Feb 26; 468(5). PMID: 26915032
Highly Cited. Review.
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Nadia M Luheshi, Jane Coates-Ulrichsen, +8 authors, Robert W Wilkinson.
Oncotarget, 2016 Feb 27; 7(14). PMID: 26918344    Free PMC article.
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Francesco Passiglia, Giuseppe Bronte, +8 authors, Antonio Russo.
Oncotarget, 2016 Feb 27; 7(15). PMID: 26918451    Free PMC article.
Highly Cited.
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
Min Luo, Liwu Fu.
Oncotarget, 2016 Feb 27; 7(20). PMID: 26919108    Free PMC article.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Jeffrey P Ward, Matthew M Gubin, Robert D Schreiber.
Adv Immunol, 2016 Mar 01; 130. PMID: 26922999    Free PMC article.
Highly Cited. Review.
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Stefani Spranger, Ayelet Sivan, Leticia Corrales, Thomas F Gajewski.
Adv Immunol, 2016 Mar 01; 130. PMID: 26923000    Free PMC article.
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Liangrong Shi, Lujun Chen, +10 authors, Jingting Jiang.
Clin Cancer Res, 2016 Mar 05; 22(5). PMID: 26933175    Free PMC article.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
Activation of cytomegalovirus-specific CD8+ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes.
Martina Schmittnaegel, Christian Klein, Victor Levitsky, Hendrik Knoetgen.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942061    Free PMC article.
PD-1 expression conditions T cell avidity within an antigen-specific repertoire.
Sylvain Simon, Virginie Vignard, +4 authors, N Labarriere.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942093    Free PMC article.
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research.
Kurt A Schalper, Edward Kaftan, Roy S Herbst.
Clin Cancer Res, 2016 Mar 10; 22(9). PMID: 26957559    Free PMC article.
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
Seung Tae Kim, Sang Yun Ha, +8 authors, Young Suk Park.
J Cancer, 2016 Mar 10; 7(5). PMID: 26958083    Free PMC article.
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Hong Zheng, Weipeng Zhao, +13 authors, Amer A Beg.
Clin Cancer Res, 2016 Mar 12; 22(16). PMID: 26964571    Free PMC article.
Highly Cited.
Vaccines for established cancer: overcoming the challenges posed by immune evasion.
Sjoerd H van der Burg, Ramon Arens, +2 authors, Cornelis J M Melief.
Nat Rev Cancer, 2016 Mar 12; 16(4). PMID: 26965076
Highly Cited. Review.
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Haidong Tang, Yang Wang, +6 authors, Yang-Xin Fu.
Cancer Cell, 2016 Mar 16; 29(3). PMID: 26977880    Free PMC article.
Highly Cited.
A role for pre-mNK cells in tumor progression.
Carolyn Rosinsky, Paul Andrew Antony.
J Immunother Cancer, 2016 Mar 17; 4. PMID: 26981246    Free PMC article.
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.
Holbrook E Kohrt, Paul C Tumeh, +33 authors, Cancer Immunotherapy Trials Network (CITN).
J Immunother Cancer, 2016 Mar 17; 4. PMID: 26981245    Free PMC article.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Tuuli Ranki, Sari Pesonen, +23 authors, Timo Joensuu.
J Immunother Cancer, 2016 Mar 17; 4. PMID: 26981247    Free PMC article.
Highly Cited.
Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.
Wei Yang, Yibing Bai, +19 authors, Chenqi Xu.
Nature, 2016 Mar 17; 531(7596). PMID: 26982734    Free PMC article.
Highly Cited.
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Stefani Spranger.
Int Immunol, 2016 Mar 19; 28(8). PMID: 26989092    Free PMC article.
Highly Cited. Review.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Clinical utility of nivolumab in the treatment of advanced melanoma.
Ramsey Asmar, Jessica Yang, Richard D Carvajal.
Ther Clin Risk Manag, 2016 Mar 26; 12. PMID: 27013881    Free PMC article.
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.
Tessa Gargett, Wenbo Yu, +6 authors, Michael P Brown.
Mol Ther, 2016 Mar 30; 24(6). PMID: 27019998    Free PMC article.
Highly Cited.
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Jill J Bastman, Hilary S Serracino, +8 authors, Jena D French.
J Clin Endocrinol Metab, 2016 Apr 06; 101(7). PMID: 27045886    Free PMC article.
The role of neoantigens in response to immune checkpoint blockade.
Nadeem Riaz, Luc Morris, +3 authors, Timothy A Chan.
Int Immunol, 2016 Apr 07; 28(8). PMID: 27048318    Free PMC article.
Immunotherapy for cancer in the central nervous system: Current and future directions.
David C Binder, Andrew A Davis, Derek A Wainwright.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057463    Free PMC article.
Highly Cited. Review.
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Nicholas Gulati, Richard D Carvajal, +2 authors, James G Krueger.
Exp Dermatol, 2016 Apr 12; 25(7). PMID: 27061281    Free PMC article.
Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?
Ila Datar, Kurt A Schalper.
Clin Cancer Res, 2016 Apr 15; 22(14). PMID: 27076625    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
Paula García-Teijido, María Luque Cabal, Ignacio Peláez Fernández, Yolanda Fernández Pérez.
Clin Med Insights Oncol, 2016 Apr 16; 10(Suppl 1). PMID: 27081325    Free PMC article.
Highly Cited. Review.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Paul T Nghiem, Shailender Bhatia, +28 authors, Martin A Cheever.
N Engl J Med, 2016 Apr 20; 374(26). PMID: 27093365    Free PMC article.
Highly Cited.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, +19 authors, Miriam Merad.
Immunity, 2016 Apr 21; 44(4). PMID: 27096321    Free PMC article.
Highly Cited.
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.
Melina E Marmarelis, Meredith R Davis, +4 authors, Patrick A Ott.
J Immunother Cancer, 2016 Apr 22; 4. PMID: 27099755    Free PMC article.
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
Malaka Ameratunga, Khashayar Asadi, +6 authors, Thomas John.
PLoS One, 2016 Apr 23; 11(4). PMID: 27104612    Free PMC article.
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Hua Wang, Liang Wang, +5 authors, Yue Lu.
Oncotarget, 2016 Apr 23; 7(22). PMID: 27105512    Free PMC article.
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
Rajarsi Mandal, Timothy A Chan.
Cancer Discov, 2016 Apr 24; 6(7). PMID: 27107038    Free PMC article.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
PD-L1 Expression in Lung Cancer.
Hui Yu, Theresa A Boyle, +2 authors, Fred R Hirsch.
J Thorac Oncol, 2016 Apr 28; 11(7). PMID: 27117833    Free PMC article.
Highly Cited. Review.
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
Hee Jin Lee, In Hye Song, +4 authors, Gyungyub Gong.
Oncotarget, 2016 Apr 29; 7(21). PMID: 27121061    Free PMC article.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Amos Kirilovsky, Florence Marliot, +3 authors, Franck Pagès.
Int Immunol, 2016 Apr 29; 28(8). PMID: 27121213    Free PMC article.
Highly Cited. Review.
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Takahiro Aoki, Moeko Hino, +8 authors, Shinichiro Motohashi.
Pediatr Blood Cancer, 2016 May 03; 63(8). PMID: 27135656    Free PMC article.
Tumor-intrinsic oncogene pathways mediating immune avoidance.
Stefani Spranger, Thomas F Gajewski.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141343    Free PMC article.
Highly Cited. Review.
A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.
Colette Dezutter-Dambuyant, Isabelle Durand, +10 authors, Christophe Caux.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141350    Free PMC article.
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.
Zachary A Cooper, Alexandre Reuben, +28 authors, Jennifer A Wargo.
Oncoimmunology, 2016 May 04; 5(3). PMID: 27141370    Free PMC article.
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Paula Kroon, Jules Gadiot, +7 authors, Inge Verbrugge.
Cancer Immunol Immunother, 2016 May 11; 65(6). PMID: 27160390    Free PMC article.
Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
Laurence Feldmeyer, Courtney W Hudgens, +16 authors, Michael T Tetzlaff.
Clin Cancer Res, 2016 May 12; 22(22). PMID: 27166398    Free PMC article.
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Seongseok Yun, Nicole D Vincelette, +2 authors, Ivo Abraham.
Cancer Med, 2016 May 12; 5(7). PMID: 27167347    Free PMC article.
Systematic Review.
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Toni K Choueiri, Mayer N Fishman, +21 authors, Mario Sznol.
Clin Cancer Res, 2016 Nov 01; 22(22). PMID: 27169994    Free PMC article.
Highly Cited.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide, Alexander Martens, +24 authors, Jedd D Wolchok.
Clin Cancer Res, 2016 Nov 01; 22(22). PMID: 27185375    Free PMC article.
Highly Cited.
Adoptive immunotherapy against ovarian cancer.
Gloria Mittica, Sonia Capellero, +4 authors, Giorgio Valabrega.
J Ovarian Res, 2016 May 18; 9(1). PMID: 27188274    Free PMC article.
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.
Yohei Masugi, Reiko Nishihara, +18 authors, Shuji Ogino.
Gut, 2016 May 20; 66(8). PMID: 27196573    Free PMC article.
Highly Cited.
Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.
Ping Jin, Yuanlong Zhao, +8 authors, David Stroncek.
Sci Rep, 2016 May 24; 6. PMID: 27211104    Free PMC article.
Oncolytic virotherapy for urological cancers.
Zahid Delwar, Kaixin Zhang, Paul S Rennie, William Jia.
Nat Rev Urol, 2016 May 25; 13(6). PMID: 27215429
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Katelyn T Byrne, Nathan H Leisenring, David L Bajor, Robert H Vonderheide.
J Immunol, 2016 May 25; 197(1). PMID: 27217585    Free PMC article.
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, +18 authors, Mari Mino-Kenudson.
Clin Cancer Res, 2016 May 27; 22(18). PMID: 27225694    Free PMC article.
Highly Cited.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, +5 authors, Paolo A Ascierto.
Drugs, 2016 May 28; 76(9). PMID: 27229745
Highly Cited. Review.
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Benjamin M Larimer, Eric Wehrenberg-Klee, Alexander Caraballo, Umar Mahmood.
J Nucl Med, 2016 May 28; 57(10). PMID: 27230929    Free PMC article.
Emerging molecular classifications and therapeutic implications for gastric cancer.
Tao Chen, Xiao-Yue Xu, Ping-Hong Zhou.
Chin J Cancer, 2016 May 29; 35. PMID: 27233623    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Monitoring immune responses in the tumor microenvironment.
Jennifer A Wargo, Sangeetha M Reddy, Alexandre Reuben, Padmanee Sharma.
Curr Opin Immunol, 2016 May 31; 41. PMID: 27240055    Free PMC article.
Landscape of tumor-infiltrating T cell repertoire of human cancers.
Bo Li, Taiwen Li, +12 authors, X Shirley Liu.
Nat Genet, 2016 May 31; 48(7). PMID: 27240091    Free PMC article.
Highly Cited.
A second chance for telomerase reverse transcriptase in anticancer immunotherapy.
Maurizio Zanetti.
Nat Rev Clin Oncol, 2016 Nov 03; 14(2). PMID: 27245281
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia.
Jonathan E Benjamin, Anthony S Stein.
Ther Adv Hematol, 2016 Jun 02; 7(3). PMID: 27247755    Free PMC article.
Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.
Jennifer S Sims, Boris Grinshpun, +7 authors, Jeffrey N Bruce.
Proc Natl Acad Sci U S A, 2016 Jun 05; 113(25). PMID: 27261081    Free PMC article.
[Molecular and immunohistochemical diagnostics in melanoma].
B Schilling, K G Griewank.
Hautarzt, 2016 Jun 09; 67(7). PMID: 27270408
What does the future hold for immunotherapy in cancer?
Jarushka Naidoo, Bob T Li, Katja Schindler, David B Page.
Ann Transl Med, 2016 Jun 09; 4(9). PMID: 27275490    Free PMC article.
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
Jae-Hyun Park, Miran Jang, +10 authors, Yusuke Nakamura.
Int J Oncol, 2016 Jun 10; 49(2). PMID: 27278091    Free PMC article.
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Woo Young Sun, Yu Kyung Lee, Ja Seung Koo.
J Transl Med, 2016 Jun 12; 14(1). PMID: 27286842    Free PMC article.
Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
Yayi He, Christopher J Rivard, +5 authors, Fred R Hirsch.
Cancer Sci, 2016 Jun 15; 107(9). PMID: 27297395    Free PMC article.
Highly Cited. Review.
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
Alimuddin Zumla, Martin Rao, Ernest Dodoo, Markus Maeurer.
BMC Med, 2016 Jun 16; 14. PMID: 27301245    Free PMC article.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling.
David J Klinke.
Mol Cell Oncol, 2016 Jun 17; 3(1). PMID: 27308541    Free PMC article.
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.
Marie Kostine, Arjen Hg Cleven, +3 authors, Judith V M G Bovée.
Mod Pathol, 2016 Jun 18; 29(9). PMID: 27312065
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
Yvonne Le Ang, Joline Sj Lim, Ross A Soo.
Onco Targets Ther, 2016 Jun 18; 9. PMID: 27313464    Free PMC article.
Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
Curr Treat Options Oncol, 2016 Jun 18; 17(8). PMID: 27315066
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Ken Hatogai, Shigehisa Kitano, +8 authors, Atsushi Ochiai.
Oncotarget, 2016 Jun 21; 7(30). PMID: 27322149    Free PMC article.
Immune checkpoint blockade therapy for bladder cancer treatment.
Jayoung Kim.
Investig Clin Urol, 2016 Jun 22; 57 Suppl 1. PMID: 27326412    Free PMC article.
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Angela Diana, Lai Mun Wang, +8 authors, Emmanouil Fokas.
Oncotarget, 2016 Jun 23; 7(27). PMID: 27329602    Free PMC article.
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Charlotte Roach, Nancy Zhang, +7 authors, Karina Kulangara.
Appl Immunohistochem Mol Morphol, 2016 Jun 23; 24(6). PMID: 27333219    Free PMC article.
Highly Cited.
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Shivshankari Rajkumar, Ian R Watson.
Br J Cancer, 2016 Jun 24; 115(2). PMID: 27336610    Free PMC article.
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Santosha Vardhana, Anas Younes.
Haematologica, 2016 Jul 02; 101(7). PMID: 27365459    Free PMC article.
Epigenetic therapy in gastrointestinal cancer: the right combination.
Eihab Abdelfatah, Zachary Kerner, Nainika Nanda, Nita Ahuja.
Therap Adv Gastroenterol, 2016 Jul 02; 9(4). PMID: 27366224    Free PMC article.
The host STING pathway at the interface of cancer and immunity.
Leticia Corrales, Sarah M McWhirter, Thomas W Dubensky, Thomas F Gajewski.
J Clin Invest, 2016 Jul 02; 126(7). PMID: 27367184    Free PMC article.
Highly Cited. Review.
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Sarah T Garber, Yuuri Hashimoto, +10 authors, Amy B Heimberger.
Neuro Oncol, 2016 Jul 03; 18(10). PMID: 27370400    Free PMC article.
Highly Cited.
High-throughput genomic profiling of tumor-infiltrating leukocytes.
Aaron M Newman, Ash A Alizadeh.
Curr Opin Immunol, 2016 Jul 04; 41. PMID: 27372732    Free PMC article.
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
Gregory L Beatty, Mark O'Hara.
Pharmacol Ther, 2016 Jul 05; 166. PMID: 27373504    Free PMC article.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Seth P Lerner, Dean F Bajorin, +33 authors, Diane Zipursky Quale.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376138    Free PMC article.
Computational genomics tools for dissecting tumour-immune cell interactions.
Hubert Hackl, Pornpimol Charoentong, Francesca Finotello, Zlatko Trajanoski.
Nat Rev Genet, 2016 Jul 05; 17(8). PMID: 27376489
Highly Cited. Review.
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors.
Deborah T Blumenthal, Michal Yalon, +6 authors, Felix Bokstein.
J Neurooncol, 2016 Jul 06; 129(3). PMID: 27377654
Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Natalie Vandeven, Paul Nghiem.
Immunotherapy, 2016 Jul 07; 8(8). PMID: 27381685    Free PMC article.
Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.
Aurélie Borrull, Bertrand Allard, +9 authors, Philippe Robin.
MAbs, 2016 Jul 09; 8(7). PMID: 27390909    Free PMC article.
Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
Tomonori Yaguchi, Yutaka Kawakami.
Int Immunol, 2016 Jul 13; 28(8). PMID: 27401477    Free PMC article.
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
Angel Qin, David G Coffey, Edus H Warren, Nithya Ramnath.
Cancer Med, 2016 Jul 16; 5(9). PMID: 27416962    Free PMC article.
Metastatic melanoma and immunotherapy.
Benjamin Herzberg, David E Fisher.
Clin Immunol, 2016 Jul 20; 172. PMID: 27430520    Free PMC article.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Louisa Mezache, Cynthia Magro, +3 authors, Gerard J Nuovo.
Appl Immunohistochem Mol Morphol, 2016 Jul 21; 25(2). PMID: 27438510    Free PMC article.
Personalized cancer vaccines: Targeting the cancer mutanome.
Xiuli Zhang, Piyush K Sharma, S Peter Goedegebuure, William E Gillanders.
Vaccine, 2016 Jul 28; 35(7). PMID: 27449681    Free PMC article.
PD-1 blockade enhances the vaccination-induced immune response in glioma.
Joseph P Antonios, Horacio Soto, +9 authors, Robert M Prins.
JCI Insight, 2016 Jul 28; 1(10). PMID: 27453950    Free PMC article.
Highly Cited.
Stem-like features of cancer cells on their way to metastasis.
Sofia Gkountela, Nicola Aceto.
Biol Direct, 2016 Jul 28; 11. PMID: 27457474    Free PMC article.
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458525    Free PMC article.
Immuno-oncology combinations: raising the tail of the survival curve.
Samuel J Harris, Jessica Brown, Juanita Lopez, Timothy A Yap.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458526    Free PMC article.
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Andrea Garofalo, Lynette Sholl, +18 authors, Eliezer M Van Allen.
Genome Med, 2016 Jul 28; 8(1). PMID: 27460824    Free PMC article.
Highly Cited.
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
Jin S Im, Amanda C Herrmann, +4 authors, Roman Perez-Soler.
PLoS One, 2016 Jul 29; 11(7). PMID: 27467256    Free PMC article.
Complete response to high-dose IL-2 and enhanced IFNγ+Th17 :  TREG ratio in a melanoma patient.
Maggie L Diller, Ragini R Kudchadkar, +2 authors, Mandy L Ford.
Melanoma Res, 2016 Jul 29; 26(5). PMID: 27467756    Free PMC article.
Melanoma driver mutations and immune therapy.
Douglas B Johnson, Christine M Lovly, +2 authors, Jeffrey A Sosman.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467925    Free PMC article.
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Adrian M Seifert, Shan Zeng, +11 authors, Ronald P DeMatteo.
Clin Cancer Res, 2016 Jul 30; 23(2). PMID: 27470968    Free PMC article.
Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.
David C Binder, Ainhoa Arina, +5 authors, Hans Schreiber.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471609    Free PMC article.
High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
Valencio Salema, Carmen Mañas, +5 authors, Luis Ángel Fernández.
MAbs, 2016 Jul 30; 8(7). PMID: 27472381    Free PMC article.
Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
Nikita L Mani, Kurt A Schalper, +6 authors, David L Rimm.
Breast Cancer Res, 2016 Jul 31; 18(1). PMID: 27473061    Free PMC article.
Immunotherapy as a Potential Treatment for Chordoma: a Review.
Shalin S Patel, Joseph H Schwab.
Curr Oncol Rep, 2016 Aug 01; 18(9). PMID: 27475804
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.
Yu Zhang, Lieping Chen.
JAMA Oncol, 2016 Aug 05; 2(11). PMID: 27490017    Free PMC article.
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Lewis Zhichang Shi, Tihui Fu, +7 authors, Padmanee Sharma.
Nat Commun, 2016 Aug 09; 7. PMID: 27498556    Free PMC article.
The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.
Sara I Pai, Dan P Zandberg, Scott E Strome.
Oral Oncol, 2016 Aug 10; 61. PMID: 27503244    Free PMC article.
Socializing Individualized T-Cell Cancer Immunotherapy.
Richard G Vile.
Mol Ther, 2016 Aug 11; 24(7). PMID: 27506377    Free PMC article.
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting.
Belal Chaudhary, Eyad Elkord.
Vaccines (Basel), 2016 Aug 12; 4(3). PMID: 27509527    Free PMC article.
Highly Cited. Review.
A Public Database of Memory and Naive B-Cell Receptor Sequences.
William S DeWitt, Paul Lindau, +7 authors, Harlan S Robins.
PLoS One, 2016 Aug 12; 11(8). PMID: 27513338    Free PMC article.
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Adil I Daud, Kimberly Loo, +15 authors, Michael D Rosenblum.
J Clin Invest, 2016 Aug 16; 126(9). PMID: 27525433    Free PMC article.
Highly Cited.
Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
Amanda W Lund, Marek Wagner, +8 authors, Melody A Swartz.
J Clin Invest, 2016 Aug 16; 126(9). PMID: 27525437    Free PMC article.
Highly Cited.
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Upasana Joneja, Semir Vranic, +7 authors, Zoran Gatalica.
J Clin Pathol, 2016 Aug 18; 70(3). PMID: 27531819    Free PMC article.
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Alain P Algazi, Katy K Tsai, +13 authors, Ryan J Sullivan.
Cancer, 2016 Oct 21; 122(21). PMID: 27533448    Free PMC article.
Highly Cited.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Alexander N Shoushtari, Rodrigo R Munhoz, +17 authors, Michael A Postow.
Cancer, 2016 Oct 21; 122(21). PMID: 27533633    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis.
Yufan Yang, ZhaoFei Pang, +5 authors, Qi Liu.
Oncotarget, 2016 Aug 20; 7(45). PMID: 27542277    Free PMC article.
Systematic Review.
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Bo Li, Eric Severson, +10 authors, X Shirley Liu.
Genome Biol, 2016 Aug 24; 17(1). PMID: 27549193    Free PMC article.
Highly Cited.
Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.
Yu Lei, Yuying Xie, +4 authors, Gregory T Wolf.
Oral Oncol, 2016 Aug 25; 61. PMID: 27553942    Free PMC article.
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Heather L McArthur, Adi Diab, +27 authors, Larry Norton.
Clin Cancer Res, 2016 Nov 05; 22(23). PMID: 27566765    Free PMC article.
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.
Hazem El-Osta, Kamran Shahid, Glenn M Mills, Prakash Peddi.
Onco Targets Ther, 2016 Aug 31; 9. PMID: 27574451    Free PMC article.
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
Michael Bruns, Jara Wanger, Udo Schumacher, Wolfgang Deppert.
Oncotarget, 2016 Sep 01; 7(40). PMID: 27579535    Free PMC article.
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
David B Page, Jianda Yuan, +22 authors, Heather L McArthur.
Cancer Immunol Res, 2016 Sep 03; 4(10). PMID: 27587469    Free PMC article.
Prognostic value of PDL1 expression in pancreatic cancer.
David J Birnbaum, Pascal Finetti, +9 authors, François Bertucci.
Oncotarget, 2016 Sep 03; 7(44). PMID: 27589570    Free PMC article.
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Blanca Homet Moreno, Jesse M Zaretsky, +11 authors, Antoni Ribas.
Cancer Immunol Res, 2016 Sep 04; 4(10). PMID: 27589875    Free PMC article.
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Maria Secrier, Xiaodun Li, +24 authors, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.
Nat Genet, 2016 Sep 07; 48(10). PMID: 27595477    Free PMC article.
Highly Cited.
Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Ronald J Fecek, Walter J Storkus.
Immunotherapy, 2016 Sep 09; 8(10). PMID: 27605069    Free PMC article.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy.
Yohei Takeda, Masahiro Azuma, Misako Matsumoto, Tsukasa Seya.
J Exp Clin Cancer Res, 2016 Sep 14; 35(1). PMID: 27619885    Free PMC article.
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Blanca Homet Moreno, Stephen Mok, +2 authors, Antoni Ribas.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622011    Free PMC article.
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chang-Long Chen, Qiu-Zhong Pan, +12 authors, Jian-Chuan Xia.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622026    Free PMC article.
Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.
Masahiro Azuma, Yohei Takeda, +5 authors, Tsukasa Seya.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622060    Free PMC article.
High-content molecular profiling of T-cell therapy in oncology.
Ruslan Novosiadly, Michael Kalos.
Mol Ther Oncolytics, 2016 Sep 15; 3. PMID: 27626060    Free PMC article.
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Akihito Kawazoe, Takeshi Kuwata, +7 authors, Atsushi Ochiai.
Gastric Cancer, 2016 Sep 16; 20(3). PMID: 27629881
Highly Cited.
Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Shalin Shah, James E Ward, +3 authors, Jason J Luke.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27638840    Free PMC article.
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.
J Galon, B A Fox, +8 authors, M Capone.
J Transl Med, 2016 Sep 22; 14. PMID: 27650038    Free PMC article.
Highly Cited.
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Archana Anantharaman, Terence Friedlander, +14 authors, Pamela L Paris.
BMC Cancer, 2016 Sep 24; 16(1). PMID: 27658492    Free PMC article.
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.
Asma Beldi-Ferchiou, Marion Lambert, +10 authors, Sophie Caillat-Zucman.
Oncotarget, 2016 Sep 24; 7(45). PMID: 27662664    Free PMC article.
Highly Cited.
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy.
Gregory S Alexander, Joshua D Palmer, +8 authors, Bo Lu.
J Hematol Oncol, 2016 Sep 25; 9(1). PMID: 27663515    Free PMC article.
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.
Darrin V Bann, Daniel G Deschler, Neerav Goyal.
Cancers (Basel), 2016 Sep 27; 8(10). PMID: 27669306    Free PMC article.
Immunotherapy for Gastroesophageal Cancer.
Emily F Goode, Elizabeth C Smyth.
J Clin Med, 2016 Sep 27; 5(10). PMID: 27669318    Free PMC article.
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Douglas B Johnson, Garrett M Frampton, +24 authors, Christine M Lovly.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27671167    Free PMC article.
Highly Cited.
CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Yingming Zhu, Minghuan Li, +7 authors, Jinming Yu.
Oncotarget, 2016 Sep 30; 7(44). PMID: 27683115    Free PMC article.
Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells.
Ishan Goswami, Sheryl Coutermarsh-Ott, +4 authors, Lissett R Bickford.
Bioelectrochemistry, 2016 Oct 04; 113. PMID: 27693939    Free PMC article.
Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.
Alessia Mennitto, Paolo Grassi, +3 authors, Giuseppe Procopio.
Ther Adv Urol, 2016 Oct 04; 8(5). PMID: 27695530    Free PMC article.
Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
David A Braun, Kelly P Burke, Eliezer M Van Allen.
Clin Cancer Res, 2016 Oct 05; 22(23). PMID: 27698000    Free PMC article.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Sumit K Subudhi, Ana Aparicio, +14 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(42). PMID: 27698113    Free PMC article.
Highly Cited.
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.
Jordan Kardos, Shengjie Chai, +8 authors, Benjamin G Vincent.
JCI Insight, 2016 Oct 05; 1(3). PMID: 27699256    Free PMC article.
Highly Cited.
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
Leila Khoja, Minnie Kibiro, +5 authors, Anthony M Joshua.
Br J Cancer, 2016 Oct 05; 115(10). PMID: 27701388    Free PMC article.
Resistance patterns to anti-PD-1 therapy in metastatic melanoma.
Alpaslan Ozgun, Vernon K Sondak, Joseph Markowitz.
Chin Clin Oncol, 2016 Oct 06; 5(6). PMID: 27701871    Free PMC article.
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.
Demytra Mitsis, Valerie Francescutti, Joseph Skitzki.
Sarcoma, 2016 Oct 06; 2016. PMID: 27703409    Free PMC article.
Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Yukiyoshi Hirayama, Min Gi, +5 authors, Hideki Wanibuchi.
Cancer Sci, 2016 Oct 07; 107(12). PMID: 27712020    Free PMC article.
Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.
Melissa Frick, Pierre Mouchacca, +7 authors, Claude Boyer.
Immunology, 2016 Nov 03; 150(2). PMID: 27716898    Free PMC article.
Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.
Zhifang Chen, Nannan Pang, +5 authors, Jianbing Ding.
Mediators Inflamm, 2016 Oct 11; 2016. PMID: 27721577    Free PMC article.
Cancer immunotherapy in patients with preexisting autoimmune disorders.
Marco Donia, Magnus Pedersen, Inge Marie Svane.
Semin Immunopathol, 2016 Oct 13; 39(3). PMID: 27730287
Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Margaretha G M Roemer, Ranjana H Advani, +13 authors, Scott J Rodig.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27737878    Free PMC article.
Highly Cited.
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.
Tsuyoshi Hamada, NaNa Keum, Reiko Nishihara, Shuji Ogino.
J Gastroenterol, 2016 Oct 16; 52(3). PMID: 27738762    Free PMC article.
Highly Cited. Review.
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
Hiroyuki Inoue, Jae-Hyun Park, +16 authors, Yusuke Nakamura.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757299    Free PMC article.
Trial Watch: Immunotherapy plus radiation therapy for oncological indications.
Erika Vacchelli, Norma Bloy, +13 authors, Lorenzo Galluzzi.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757313    Free PMC article.
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Yoshio Nakamura, Shigehisa Kitano, +8 authors, Naoya Yamazaki.
Oncotarget, 2016 Oct 21; 7(47). PMID: 27764805    Free PMC article.
Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.
Joseph M Obeid, Nolan A Wages, +2 authors, Craig L Slingluff.
Cancer Immunol Immunother, 2016 Oct 23; 66(1). PMID: 27770170    Free PMC article.
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.
Neil M D'Souza, Penny Fang, +3 authors, Jing Li.
Front Oncol, 2016 Oct 25; 6. PMID: 27774435    Free PMC article.
Radiotherapy: Changing the Game in Immunotherapy.
Sandra Demaria, C Norman Coleman, Silvia C Formenti.
Trends Cancer, 2016 Oct 25; 2(6). PMID: 27774519    Free PMC article.
Highly Cited. Review.
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Genevieve M Weir, Olga Hrytsenko, +3 authors, Marc Mansour.
J Immunother Cancer, 2016 Oct 26; 4. PMID: 27777777    Free PMC article.
Lymphocyte activation gene 3 and coronary artery disease.
Diana Golden, Antonina Kolmakova, +8 authors, Annabelle Rodriguez.
JCI Insight, 2016 Oct 26; 1(17). PMID: 27777974    Free PMC article.
The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal, Yasin Şenbabaoğlu, +8 authors, Luc Gt Morris.
JCI Insight, 2016 Oct 26; 1(17). PMID: 27777979    Free PMC article.
Highly Cited.
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
E Ilett, T Kottke, +12 authors, R Vile.
Gene Ther, 2016 Oct 26; 24(1). PMID: 27779616    Free PMC article.
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.
Erin A Marshall, Kevin W Ng, +15 authors, Wan L Lam.
Mol Cancer, 2016 Oct 28; 15(1). PMID: 27784305    Free PMC article.
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Ju Yeon Lee, Hyun Tae Lee, +11 authors, Yong-Seok Heo.
Nat Commun, 2016 Nov 01; 7. PMID: 27796306    Free PMC article.
Highly Cited.
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Shu Wang, Jose Campos, +5 authors, Cristiana Guiducci.
Proc Natl Acad Sci U S A, 2016 Nov 02; 113(46). PMID: 27799536    Free PMC article.
Highly Cited.
Recent advances in understanding antitumor immunity.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
F1000Res, 2016 Nov 03; 5. PMID: 27803807    Free PMC article.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Douglas B Johnson, Justin M Balko, +29 authors, Javid J Moslehi.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806233    Free PMC article.
Highly Cited.
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Vassiliki A Boussiotis.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806234    Free PMC article.
Highly Cited. Review.
Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Ann Margaret V Chang, Simion I Chiosea, +2 authors, Changqing Ma.
Head Neck Pathol, 2016 Nov 04; 11(2). PMID: 27807760    Free PMC article.
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Claudia Zelle-Rieser, Shanmugapriya Thangavadivel, +5 authors, Karin Jöhrer.
J Hematol Oncol, 2016 Nov 05; 9(1). PMID: 27809856    Free PMC article.
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Shuguang Tan, Danqing Chen, +9 authors, George F Gao.
Protein Cell, 2016 Nov 07; 7(12). PMID: 27815822    Free PMC article.
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Xiaohong Wang, Jonathan E Schoenhals, +18 authors, James W Welsh.
Cancer Res, 2016 Nov 09; 77(4). PMID: 27821490    Free PMC article.
Highly Cited.
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Wei Xue, Victoria A Brentville, +4 authors, Lindy G Durrant.
Oncotarget, 2016 Nov 09; 7(50). PMID: 27825115    Free PMC article.
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity.
Thomas R Flint, Tobias Janowitz, +5 authors, Douglas T Fearon.
Cell Metab, 2016 Nov 10; 24(5). PMID: 27829137    Free PMC article.
Highly Cited.
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.
Monica Marzagalli, Marina Montagnani Marelli, +3 authors, Patrizia Limonta.
Front Endocrinol (Lausanne), 2016 Nov 12; 7. PMID: 27833586    Free PMC article.
Gene-expression profiling to predict responsiveness to immunotherapy.
N B Jamieson, A V Maker.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834354    Free PMC article.
Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Ameet K Mishra, Tanya Kadoishi, +4 authors, Jing H Wang.
Oncotarget, 2016 Nov 12; 7(49). PMID: 27835902    Free PMC article.
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Randy F Sweis, Matthew D Galsky.
Urol Oncol, 2016 Nov 12; 34(12). PMID: 27836246    Free PMC article.
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Stefani Spranger, Jason J Luke, +6 authors, Thomas F Gajewski.
Proc Natl Acad Sci U S A, 2016 Nov 12; 113(48). PMID: 27837020    Free PMC article.
Highly Cited.
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Ludmila Danilova, Hao Wang, +9 authors, Janis M Taube.
Proc Natl Acad Sci U S A, 2016 Nov 12; 113(48). PMID: 27837027    Free PMC article.
Highly Cited.
Recent advances in the biology of human circulating tumour cells and metastasis.
Sofia Gkountela, Barbara Szczerba, Cinzia Donato, Nicola Aceto.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843628    Free PMC article.
Immune-related response criteria: light and shadows.
Marco Merlano, Marcella Occelli, Ornella Garrone.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843632    Free PMC article.
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Yayan T Sundara, Marie Kostine, +3 authors, Anne-Marie Cleton-Jansen.
Cancer Immunol Immunother, 2016 Nov 18; 66(1). PMID: 27853827    Free PMC article.
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Yasin Şenbabaoğlu, Ron S Gejman, +26 authors, A Ari Hakimi.
Genome Biol, 2016 Nov 20; 17(1). PMID: 27855702    Free PMC article.
Highly Cited.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Adil I Daud, Jedd D Wolchok, +21 authors, Omid Hamid.
J Clin Oncol, 2016 Nov 20; 34(34). PMID: 27863197    Free PMC article.
Highly Cited.
Next generation predictive biomarkers for immune checkpoint inhibition.
Yulian Khagi, Razelle Kurzrock, Sandip Pravin Patel.
Cancer Metastasis Rev, 2016 Nov 23; 36(1). PMID: 27873079    Free PMC article.
TCR diversity - a universal cancer immunotherapy biomarker?
Douglas G McNeel.
J Immunother Cancer, 2016 Nov 24; 4. PMID: 27879971    Free PMC article.
Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma.
Qiaoshi Xu, Chong Wang, +2 authors, Zhengxue Han.
Transl Oncol, 2016 Nov 27; 10(1). PMID: 27888708    Free PMC article.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu-Lieskovan.
J Exp Med, 2016 Dec 03; 213(13). PMID: 27903604    Free PMC article.
Highly Cited. Review.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.
Benjamin E Paluch, Sean T Glenn, +14 authors, Carl D Morrison.
Oncotarget, 2016 Dec 03; 8(2). PMID: 27911273    Free PMC article.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L Benci, Bihui Xu, +16 authors, Andy J Minn.
Cell, 2016 Dec 03; 167(6). PMID: 27912061    Free PMC article.
Highly Cited.
Pharmacological and immunological targeting of tumor mesenchymalization.
Justin M David, Charli Dominguez, Claudia Palena.
Pharmacol Ther, 2016 Dec 06; 170. PMID: 27916651    Free PMC article.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins.
Lancet Oncol, 2016 Dec 08; 17(12). PMID: 27924752    Free PMC article.
Highly Cited. Review.
Melanoma exosomes deliver a complex biological payload that upregulates PTPN11 to suppress T lymphocyte function.
Yueting Wu, Wentao Deng, Emily Chambers McGinley, David J Klinke.
Pigment Cell Melanoma Res, 2016 Dec 09; 30(2). PMID: 27930879    Free PMC article.
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade.
Tavi Nathanson, Arun Ahuja, +8 authors, Jeff Hammerbacher.
Cancer Immunol Res, 2016 Dec 14; 5(1). PMID: 27956380    Free PMC article.
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.
Mack Y Su, David E Fisher.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959922    Free PMC article.
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.
Xiaopin Duan, Christina Chan, +3 authors, Wenbin Lin.
J Am Chem Soc, 2016 Dec 16; 138(51). PMID: 27976881    Free PMC article.
Innate immune signaling and regulation in cancer immunotherapy.
Leticia Corrales, Vyara Matson, +2 authors, Thomas F Gajewski.
Cell Res, 2016 Dec 17; 27(1). PMID: 27981969    Free PMC article.
Highly Cited. Review.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases.
Zeynep Koşaloğlu, Inka Zörnig, +7 authors, Dirk Jäger.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999735    Free PMC article.
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Joseph M Obeid, Gulsun Erdag, +5 authors, Craig L Slingluff.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999753    Free PMC article.
CAR T-cell therapy of solid tumors.
Carmen S M Yong, Valerie Dardalhon, +3 authors, Michael H Kershaw.
Immunol Cell Biol, 2016 Dec 23; 95(4). PMID: 28003642
Highly Cited. Review.
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Valérie Dutoit, Denis Migliorini, Pierre-Yves Dietrich, Paul R Walker.
Front Oncol, 2016 Dec 23; 6. PMID: 28003994    Free PMC article.
LIGHTing tumor up for checkpoint blockade.
Yong Liang, Hua Peng.
Oncotarget, 2016 Dec 23; 7(31). PMID: 28004636    Free PMC article.
Improved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates.
Whitney A Young, Eleanor A Fallon, +3 authors, Alfred Ayala.
Surgery, 2016 Dec 26; 161(5). PMID: 28012568    Free PMC article.
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Kankana Bardhan, Theodora Anagnostou, Vassiliki A Boussiotis.
Front Immunol, 2016 Dec 27; 7. PMID: 28018338    Free PMC article.
Highly Cited. Review.
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Andrew S Flies, A Bruce Lyons, +5 authors, John D Hayball.
Front Immunol, 2016 Dec 27; 7. PMID: 28018348    Free PMC article.
Focus on Nivolumab in NSCLC.
Diego L Cortinovis, Stefania Canova, +2 authors, Paolo Bidoli.
Front Med (Lausanne), 2016 Dec 27; 3. PMID: 28018902    Free PMC article.
Driving gene-engineered T cell immunotherapy of cancer.
Laura A Johnson, Carl H June.
Cell Res, 2016 Dec 28; 27(1). PMID: 28025979    Free PMC article.
Highly Cited. Review.
Update on immune checkpoint inhibitors in gynecological cancers.
Valerie Heong, Natalie Ngoi, David Shao Peng Tan.
J Gynecol Oncol, 2016 Dec 29; 28(2). PMID: 28028993    Free PMC article.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, +26 authors, Victor E Velculescu.
Cancer Discov, 2016 Dec 30; 7(3). PMID: 28031159    Free PMC article.
Highly Cited.
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Theodore S Nowicki, Ryan Akiyama, +8 authors, Antoni Ribas.
Cancer Immunol Res, 2017 Jan 01; 5(2). PMID: 28039162    Free PMC article.
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Dongxian Jiang, Qi Song, +9 authors, Yingyong Hou.
Oncotarget, 2017 Jan 01; 8(5). PMID: 28039448    Free PMC article.
Immunoplasticity in cutaneous melanoma: beyond pure morphology.
Francesca Maria Bosisio, Joost J van den Oord.
Virchows Arch, 2017 Jan 06; 470(4). PMID: 28054151
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.
M González-Cao, A Arance, +22 authors, Spanish Melanoma Group.
Clin Transl Oncol, 2017 Jan 06; 19(6). PMID: 28054320
Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
Karla Parra, Paloma Valenzuela, +10 authors, Giulio Francia.
Br J Cancer, 2017 Jan 06; 116(3). PMID: 28056464    Free PMC article.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
W Joost Lesterhuis, Anthony Bosco, +3 authors, Richard A Lake.
Nat Rev Drug Discov, 2017 Jan 07; 16(4). PMID: 28057932
Highly Cited. Review.
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Kenneth G Liu, Sorab Gupta, Sanjay Goel.
Oncotarget, 2017 Jan 07; 8(10). PMID: 28061473    Free PMC article.
Reducing persistent polyomavirus infection increases functionality of virus-specific memory CD8 T cells.
Qingsong Qin, Matthew Lauver, +2 authors, Aron E Lukacher.
Virology, 2017 Jan 08; 502. PMID: 28063344    Free PMC article.
T cell receptor repertoire usage in cancer as a surrogate marker for immune responses.
David Schrama, Cathrin Ritter, Jürgen C Becker.
Semin Immunopathol, 2017 Jan 12; 39(3). PMID: 28074285
Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.
Natalie J Miller, Candice D Church, +11 authors, Paul Nghiem.
Cancer Immunol Res, 2017 Jan 18; 5(2). PMID: 28093446    Free PMC article.
Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells.
Hui Liu, Min Zhu, +4 authors, Weicheng Xue.
J Cancer Res Clin Oncol, 2017 Jan 18; 143(4). PMID: 28093638
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu.
Nat Rev Clin Oncol, 2017 Jan 18; 14(6). PMID: 28094262
Highly Cited. Review.
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.
Kenji Chamoto, Partha S Chowdhury, +4 authors, Tasuku Honjo.
Proc Natl Acad Sci U S A, 2017 Jan 18; 114(5). PMID: 28096382    Free PMC article.
Highly Cited.
Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation.
David J Klinke, Qing Wang.
Front Pharmacol, 2017 Jan 20; 7. PMID: 28101055    Free PMC article.
Elements of cancer immunity and the cancer-immune set point.
Daniel S Chen, Ira Mellman.
Nature, 2017 Jan 20; 541(7637). PMID: 28102259
Highly Cited. Review.
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
Teresa Davoli, Hajime Uno, Eric C Wooten, Stephen J Elledge.
Science, 2017 Jan 21; 355(6322). PMID: 28104840    Free PMC article.
Highly Cited.
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Kathryn E Beckermann, Pradeep C Jolly, +4 authors, Douglas B Johnson.
J Immunother Cancer, 2017 Jan 21; 5. PMID: 28105368    Free PMC article.
T-cell receptor-engineered T cells for cancer treatment: current status and future directions.
Yu Ping, Chaojun Liu, Yi Zhang.
Protein Cell, 2017 Jan 22; 9(3). PMID: 28108950    Free PMC article.
Highly Cited. Review.
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
Jason B Williams, Brendan L Horton, +3 authors, Thomas F Gajewski.
J Exp Med, 2017 Jan 25; 214(2). PMID: 28115575    Free PMC article.
Highly Cited.
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Joseph P Antonios, Horacio Soto, +12 authors, Robert M Prins.
Neuro Oncol, 2017 Jan 25; 19(6). PMID: 28115578    Free PMC article.
Highly Cited.
Tumour-associated macrophages as treatment targets in oncology.
Alberto Mantovani, Federica Marchesi, +2 authors, Paola Allavena.
Nat Rev Clin Oncol, 2017 Jan 25; 14(7). PMID: 28117416    Free PMC article.
Highly Cited. Review.
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Kenneth Oguejiofor, Henry Galletta-Williams, +3 authors, Catharine M L West.
Oncotarget, 2017 Jan 26; 8(9). PMID: 28122336    Free PMC article.
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Marcel A Deken, Jules Gadiot, +13 authors, Christian U Blank.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123875    Free PMC article.
Highly Cited.
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.
Isabel Poschke, Marta Faryna, +19 authors, Rienk Offringa.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123878    Free PMC article.
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.
Yumi Nonomura, Atsushi Otsuka, +14 authors, Kenji Kabashima.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123885    Free PMC article.
Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.
Frederick S Varn, Yue Wang, +2 authors, Chao Cheng.
Cancer Res, 2017 Jan 28; 77(6). PMID: 28126714    Free PMC article.
Highly Cited.
Neutrophils dominate the immune cell composition in non-small cell lung cancer.
Julia Kargl, Stephanie E Busch, +8 authors, A McGarry Houghton.
Nat Commun, 2017 Feb 02; 8. PMID: 28146145    Free PMC article.
Highly Cited.
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
Chul Kim, Arun Rajan, Pedro A DeBrito, Giuseppe Giaccone.
Transl Lung Cancer Res, 2017 Feb 06; 5(6). PMID: 28149767    Free PMC article.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Applications of Immunogenomics to Cancer.
X Shirley Liu, Elaine R Mardis.
Cell, 2017 Feb 12; 168(4). PMID: 28187283    Free PMC article.
Highly Cited. Review.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Maria L Ascierto, Alvin Makohon-Moore, +18 authors, Suzanne L Topalian.
Clin Cancer Res, 2017 Feb 15; 23(12). PMID: 28193624    Free PMC article.
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.
Andrew M K Law, Elgene Lim, Christopher J Ormandy, David Gallego-Ortega.
Endocr Relat Cancer, 2017 Feb 15; 24(4). PMID: 28193698    Free PMC article.
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Laurence Buisseret, Soizic Garaud, +14 authors, Karen Willard-Gallo.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197375    Free PMC article.
Highly Cited.
Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.
Marta Usó, Eloísa Jantus-Lewintre, +6 authors, Rafael Sirera.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197383    Free PMC article.
Emerging role of checkpoint blockade therapy in lymphoma.
Natalie Galanina, Justin Kline, Michael R Bishop.
Ther Adv Hematol, 2017 Feb 17; 8(2). PMID: 28203344    Free PMC article.
Targeting PD-1/PD-L1 in lung cancer: current perspectives.
María González-Cao, Niki Karachaliou, +6 authors, Rafael Rosell.
Lung Cancer (Auckl), 2015 Jul 31; 6. PMID: 28210151    Free PMC article.
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
Kai Li, Shuai Qu, +2 authors, Ming Shi.
Int J Mol Sci, 2017 Feb 22; 18(2). PMID: 28216575    Free PMC article.
Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity.
Kim Pin Yeo, Veronique Angeli.
Front Immunol, 2017 Feb 22; 8. PMID: 28220121    Free PMC article.
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
Van K Morris, Mohamed E Salem, +26 authors, Cathy Eng.
Lancet Oncol, 2017 Feb 23; 18(4). PMID: 28223062    Free PMC article.
Highly Cited.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Kevin G Shim, Shane Zaidi, +8 authors, Richard G Vile.
Mol Ther, 2017 Feb 27; 25(4). PMID: 28237836    Free PMC article.
Immunotherapy resistance: the answers lie ahead - not in front - of us.
Miles C Andrews, Jennifer A Wargo.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239464    Free PMC article.
3D: diversity, dynamics, differential testing - a proposed pipeline for analysis of next-generation sequencing T cell repertoire data.
Li Zhang, Jason Cham, +3 authors, Lawrence Fong.
BMC Bioinformatics, 2017 Mar 01; 18(1). PMID: 28241742    Free PMC article.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, +37 authors, P Andrew Futreal.
Sci Transl Med, 2017 Mar 03; 9(379). PMID: 28251903    Free PMC article.
Highly Cited.
Dual Roles of IL-27 in Cancer Biology and Immunotherapy.
Marina Fabbi, Grazia Carbotti, Silvano Ferrini.
Mediators Inflamm, 2017 Mar 04; 2017. PMID: 28255204    Free PMC article.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.
Yemsratch T Akalu, Carla V Rothlin, Sourav Ghosh.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258690    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC.
J E Mann, R Hoesli, +9 authors, J C Brenner.
J Cancer, 2017 Mar 07; 8(3). PMID: 28261333    Free PMC article.
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Elias J Sayour, Duane A Mitchell.
J Immunol Res, 2017 Mar 08; 2017. PMID: 28265580    Free PMC article.
The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.
Xueheng Guo, Ning Wu, +7 authors, Li Wu.
Front Immunol, 2017 Mar 09; 8. PMID: 28270814    Free PMC article.
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.
Jiaying Wu, Dongsheng Hong, +2 authors, Jing Miao.
Sci Rep, 2017 Mar 09; 7. PMID: 28272463    Free PMC article.
ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Chi-Fen Chen, Rolando Ruiz-Vega, +9 authors, Anand K Ganesan.
Cell Rep, 2017 Mar 09; 18(10). PMID: 28273450    Free PMC article.
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Yayi He, Leslie Rozeboom, +5 authors, Fred R Hirsch.
Med Sci Monit, 2017 Mar 10; 23. PMID: 28275222    Free PMC article.
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Alice O Kamphorst, Andreas Wieland, +17 authors, Rafi Ahmed.
Science, 2017 Mar 11; 355(6332). PMID: 28280249    Free PMC article.
Highly Cited.
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Motonobu Saito, Hiroyuki Suzuki, +2 authors, Takashi Kohno.
Surg Today, 2017 Mar 11; 48(1). PMID: 28280984
Functio Laesa: Cancer Inflammation and Therapeutic Resistance.
Mingen Liu, Anusha Kalbasi, Gregory L Beatty.
J Oncol Pract, 2017 Mar 11; 13(3). PMID: 28282278    Free PMC article.
Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells.
Giuliana P Mognol, Roberto Spreafico, +6 authors, Sara Trifari.
Proc Natl Acad Sci U S A, 2017 Mar 12; 114(13). PMID: 28283662    Free PMC article.
Highly Cited.
Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.
Todd A Aguilera, Amato J Giaccia.
Clin Cancer Res, 2017 Mar 16; 23(12). PMID: 28289089    Free PMC article.
Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
Reetobrata Basu, Nicholas Baumgaertel, Shiyong Wu, John J Kopchick.
Horm Cancer, 2017 Mar 16; 8(3). PMID: 28293855
Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma.
Satoshi Tsutsumi, Hiroshi Saeki, +6 authors, Yoshihiko Maehara.
Cancer Sci, 2017 Mar 16; 108(6). PMID: 28294486    Free PMC article.
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Vikram R Juneja, Kathleen A McGuire, +5 authors, Arlene H Sharpe.
J Exp Med, 2017 Mar 18; 214(4). PMID: 28302645    Free PMC article.
Highly Cited.
DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.
Elfriede Noessner.
Front Cell Dev Biol, 2017 Mar 21; 5. PMID: 28316970    Free PMC article.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Randy F Sweis, Jason J Luke.
Pharmacol Res, 2017 Mar 23; 120. PMID: 28323141    Free PMC article.
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Jennifer D Moy, Jessica M Moskovitz, Robert L Ferris.
Eur J Cancer, 2017 Mar 23; 76. PMID: 28324750    Free PMC article.
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
Adi Nosrati, Katy K Tsai, +9 authors, Adil Daud.
Br J Cancer, 2017 Mar 23; 116(9). PMID: 28324889    Free PMC article.
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
Laurence P Diggs, Eddy C Hsueh.
Biomark Res, 2017 Mar 24; 5. PMID: 28331612    Free PMC article.
Highly Cited. Review.
Systematic evaluation of immune regulation and modulation.
David F Stroncek, Lisa H Butterfield, +12 authors, Barbara Seliger.
J Immunother Cancer, 2017 Mar 24; 5. PMID: 28331613    Free PMC article.
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
James W Smithy, Lauren M Moore, +7 authors, David L Rimm.
J Immunother Cancer, 2017 Mar 24; 5. PMID: 28331615    Free PMC article.
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Takashi Nomizo, Hiroaki Ozasa, +8 authors, Young Hak Kim.
Sci Rep, 2017 Mar 24; 7. PMID: 28332580    Free PMC article.
Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells.
Bo Xiang, Trevor R Baybutt, +4 authors, Adam E Snook.
J Immunol, 2017 Mar 28; 198(9). PMID: 28341670    Free PMC article.
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.
Florine A Eggink, Inge C Van Gool, +11 authors, Tjalling Bosse.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344870    Free PMC article.
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.
Inna Serganova, Ekaterina Moroz, +6 authors, Ronald Blasberg.
Mol Ther Oncolytics, 2017 Mar 28; 4. PMID: 28345023    Free PMC article.
Molecular genetic and immunotherapeutic targets in metastatic melanoma.
C Melis, A Rogiers, O Bechter, Joost J van den Oord.
Virchows Arch, 2017 Mar 31; 471(2). PMID: 28357489
Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.
Aude G Chapuis, Cindy Desmarais, +11 authors, Cassian Yee.
Sci Immunol, 2017 Apr 04; 2(8). PMID: 28367538    Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway.
Pablo Penaloza-MacMaster.
Immunology, 2017 Apr 05; 151(2). PMID: 28375543    Free PMC article.
Cancer immunotherapies targeting the PD-1 signaling pathway.
Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo.
J Biomed Sci, 2017 Apr 06; 24(1). PMID: 28376884    Free PMC article.
Highly Cited. Review.
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
Haruki Kobayashi, Shota Omori, +7 authors, Toshiaki Takahashi.
Int J Clin Oncol, 2017 Apr 07; 22(4). PMID: 28382561
Tumor Vaccines for Malignant Gliomas.
Visish M Srinivasan, Sherise D Ferguson, +3 authors, Amy B Heimberger.
Neurotherapeutics, 2017 Apr 09; 14(2). PMID: 28389997    Free PMC article.
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma.
Daniel Y Wang, Zeynep Eroglu, +11 authors, Elizabeth I Buchbinder.
Cancer Immunol Res, 2017 Apr 12; 5(5). PMID: 28396509    Free PMC article.
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis.
Qiang Liu, Chun-Sheng Li.
Chin Med J (Engl), 2017 Apr 12; 130(8). PMID: 28397730    Free PMC article.
Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.
Zhenyu Zhong, Yougang Zhai, +2 authors, Liang Qiao.
Nat Commun, 2017 Apr 12; 8. PMID: 28397782    Free PMC article.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, +31 authors, E John Wherry.
Nature, 2017 Apr 12; 545(7652). PMID: 28397821    Free PMC article.
Highly Cited.
Indicators of responsiveness to immune checkpoint inhibitors.
Bradley D Shields, Fade Mahmoud, +10 authors, Alan J Tackett.
Sci Rep, 2017 Apr 13; 7(1). PMID: 28400597    Free PMC article.
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Pauline Gravelle, Barbara Burroni, +7 authors, Camille Laurent.
Oncotarget, 2017 Apr 14; 8(27). PMID: 28402953    Free PMC article.
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, +8 authors, Gabriele Bergers.
Sci Transl Med, 2017 Apr 14; 9(385). PMID: 28404866    Free PMC article.
Highly Cited.
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.
Andres Lopez-Albaitero, Hong Xu, +8 authors, Nai-Kong V Cheung.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405494    Free PMC article.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Paul C Tumeh, Matthew D Hellmann, +31 authors, Adil Daud.
Cancer Immunol Res, 2017 Apr 16; 5(5). PMID: 28411193    Free PMC article.
Highly Cited.
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Jiwon Koh, Chan-Young Ock, +8 authors, Hye Seung Lee.
Oncotarget, 2017 Apr 17; 8(16). PMID: 28412752    Free PMC article.
Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine.
Zhida Liu, Chang Zhou, +10 authors, Wei Liang.
Cell Discov, 2017 Apr 19; 3. PMID: 28417012    Free PMC article.
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Melita Irving, Romain Vuillefroy de Silly, +2 authors, George Coukos.
Front Immunol, 2017 Apr 20; 8. PMID: 28421069    Free PMC article.
[The pathology of adverse events with immune checkpoint inhibitors].
V H Koelzer, K Glatz, +7 authors, K D Mertz.
Pathologe, 2017 Apr 20; 38(3). PMID: 28421272
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Joel C Sunshine, Peter L Nguyen, +10 authors, Janis M Taube.
Clin Cancer Res, 2017 Apr 22; 23(16). PMID: 28428193    Free PMC article.
Highly Cited.
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
Luc Cabel, Elika Loir, +6 authors, Karim Fizazi.
J Immunother Cancer, 2017 Apr 22; 5. PMID: 28428880    Free PMC article.
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma.
Dagmar Kollmann, Desislava Ignatova, +13 authors, Sebastian F Schoppmann.
Ann Surg Oncol, 2017 Apr 22; 24(9). PMID: 28429196    Free PMC article.
The use of immunotherapy in the treatment of melanoma.
Tala Achkar, Ahmad A Tarhini.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434398    Free PMC article.
A STING-activating nanovaccine for cancer immunotherapy.
Min Luo, Hua Wang, +13 authors, Jinming Gao.
Nat Nanotechnol, 2017 Apr 25; 12(7). PMID: 28436963    Free PMC article.
Highly Cited.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Alice O Kamphorst, Rathi N Pillai, +16 authors, Suresh S Ramalingam.
Proc Natl Acad Sci U S A, 2017 Apr 28; 114(19). PMID: 28446615    Free PMC article.
Highly Cited.
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer.
Julienne L Carstens, Pedro Correa de Sampaio, +6 authors, Raghu Kalluri.
Nat Commun, 2017 Apr 28; 8. PMID: 28447602    Free PMC article.
Highly Cited.
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Liyan Jiang, Xinying Su, +18 authors, Yi Gu.
Oncotarget, 2017 May 04; 8(16). PMID: 28460468    Free PMC article.
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Benjamin M Larimer, Eric Wehrenberg-Klee, +5 authors, Umar Mahmood.
Cancer Res, 2017 May 04; 77(9). PMID: 28461564    Free PMC article.
Highly Cited.
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Seth M Pollack, Qianchuan He, +21 authors, Robin L Jones.
Cancer, 2017 May 04; 123(17). PMID: 28463396    Free PMC article.
Highly Cited.
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
Joao Paulo da Silveira Nogueira Lima, Mina Georgieva, Benjamin Haaland, Gilberto de Lima Lopes.
Cancer Med, 2017 May 04; 6(6). PMID: 28463413    Free PMC article.
Systematic Review.
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kyoung-Jin Kim, Ji-Hye Kim, +3 authors, Jinsil Seong.
Oncotarget, 2017 May 04; 8(25). PMID: 28465485    Free PMC article.
Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.
Jay M Lee, Mi-Heon Lee, +23 authors, Steven M Dubinett.
Clin Cancer Res, 2017 May 05; 23(16). PMID: 28468947    Free PMC article.
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Heath D Skinner, Uma Giri, +15 authors, John V Heymach.
Clin Cancer Res, 2017 May 10; 23(11). PMID: 28476872    Free PMC article.
Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.
Simon Vyse, Annie Howitt, Paul H Huang.
J Mol Biol, 2017 May 10; 429(12). PMID: 28478283    Free PMC article.
Pembrolizumab-induced pneumonitis.
Vincent Leroy, Carole Templier, +4 authors, Lidwine Wemeau-Stervinou.
ERJ Open Res, 2017 May 10; 3(2). PMID: 28480216    Free PMC article.
Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
Esra A Akbay, Shohei Koyama, +21 authors, Kwok-Kin Wong.
J Thorac Oncol, 2017 May 10; 12(8). PMID: 28483607    Free PMC article.
Highly Cited.
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
Jeremy B Foote, Marleen Kok, +7 authors, Leisha A Emens.
Cancer Immunol Res, 2017 May 10; 5(6). PMID: 28483787    Free PMC article.
Highly Cited.
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Kaiyuan Wang, Jian Wang, +3 authors, Xiubao Ren.
Front Immunol, 2017 May 10; 8. PMID: 28484456    Free PMC article.
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger, Daisy Dai, Brendan Horton, Thomas F Gajewski.
Cancer Cell, 2017 May 10; 31(5). PMID: 28486109    Free PMC article.
Highly Cited.
Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.
Kentaro Inamura.
Cancers (Basel), 2017 May 10; 9(5). PMID: 28486396    Free PMC article.
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.
David H Munn, Madhav D Sharma, Theodore S Johnson, Paulo Rodriguez.
Cancer Immunol Immunother, 2017 May 11; 66(8). PMID: 28488123    Free PMC article.
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Upendra P Hegde, Bijay Mukherji.
Cancer Immunol Immunother, 2017 May 13; 66(9). PMID: 28497159    Free PMC article.
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
Marc C Chamberlain, Bryan T Kim.
J Neurooncol, 2017 May 14; 133(3). PMID: 28500559
Implementing liquid biopsies into clinical decision making for cancer immunotherapy.
Dagmar Quandt, Hans Dieter Zucht, +19 authors, Barbara Seliger.
Oncotarget, 2017 May 16; 8(29). PMID: 28501851    Free PMC article.
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.
Jun Ren, William R Gwin, +11 authors, H Kim Lyerly.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507788    Free PMC article.
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Hélène Roussel, Eléonore De Guillebon, +18 authors, Eric Tartour.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507793    Free PMC article.
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment.
Giulia Chiaruttini, Silvia Mele, +4 authors, Sophia N Karagiannis.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507802    Free PMC article.
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.
Peter J Siska, Romany A N Johnpulle, +9 authors, Douglas B Johnson.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507813    Free PMC article.
Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Delong Liu, Shuhang Wang, Wendy Bindeman.
J Hematol Oncol, 2017 May 19; 10(1). PMID: 28514966    Free PMC article.
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, +13 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515944    Free PMC article.
Highly Cited. Review.
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Jun Zhou, Kathleen M Mahoney, +13 authors, F Stephen Hodi.
Cancer Immunol Res, 2017 May 20; 5(6). PMID: 28522460    Free PMC article.
Highly Cited.
Hallmarks of response to immune checkpoint blockade.
Alexandria P Cogdill, Miles C Andrews, Jennifer A Wargo.
Br J Cancer, 2017 May 20; 117(1). PMID: 28524159    Free PMC article.
Highly Cited. Review.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Rance C Siniard, Shuko Harada.
Virchows Arch, 2017 May 22; 471(2). PMID: 28528510
Current state of immunotherapy for non-small cell lung cancer.
Jyoti Malhotra, Salma K Jabbour, Joseph Aisner.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529902    Free PMC article.
Highly Cited. Review.
Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer.
Allison M Campbell, Roy H Decker.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529904    Free PMC article.
High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.
Luis Felipe Campesato, Ana Paula M Silva, +17 authors, Anamaria A Camargo.
Oncotarget, 2017 May 24; 8(30). PMID: 28533483    Free PMC article.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.
Carlos A Morales-Betanzos, Hyoungjoo Lee, +4 authors, Daniel C Liebler.
Mol Cell Proteomics, 2017 May 27; 16(10). PMID: 28546465    Free PMC article.
Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.
Sandra M Kallert, Stephanie Darbre, +12 authors, Daniel D Pinschewer.
Nat Commun, 2017 May 27; 8. PMID: 28548102    Free PMC article.
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Alexandra Snyder, Tavi Nathanson, +18 authors, Dean F Bajorin.
PLoS Med, 2017 May 30; 14(5). PMID: 28552987    Free PMC article.
Highly Cited.
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Jingyu Zhang, Dai Liu, +4 authors, Jennifer D Wu.
Sci Adv, 2017 Jun 01; 3(5). PMID: 28560327    Free PMC article.
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Antje Sucker, Fang Zhao, +20 authors, Annette Paschen.
Nat Commun, 2017 Jun 01; 8. PMID: 28561041    Free PMC article.
Highly Cited.
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Nicholas M Durham, Kathy Mulgrew, +6 authors, Elizabeth J Kelly.
Mol Ther, 2017 Jun 06; 25(8). PMID: 28578991    Free PMC article.
Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents.
Farid G Khalafalla, Mohammad W Khan.
Cancer Growth Metastasis, 2017 Jun 06; 10. PMID: 28579826    Free PMC article.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, +43 authors, Luis A Diaz.
Science, 2017 Jun 10; 357(6349). PMID: 28596308    Free PMC article.
Highly Cited.
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
C Brüggemann, M C Kirchberger, +14 authors, L Heinzerling.
J Cancer Res Clin Oncol, 2017 Jun 16; 143(10). PMID: 28616701
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.
Anusha-Preethi Ganesan, James Clarke, +14 authors, Christian H Ottensmeier.
Nat Immunol, 2017 Jun 20; 18(8). PMID: 28628092    Free PMC article.
Highly Cited.
DNA Damage and Repair Biomarkers of Immunotherapy Response.
Kent W Mouw, Michael S Goldberg, Panagiotis A Konstantinopoulos, Alan D D'Andrea.
Cancer Discov, 2017 Jun 21; 7(7). PMID: 28630051    Free PMC article.
Highly Cited. Review.
A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Anurag K Singh, Timothy B Winslow, +13 authors, Jason B Muhitch.
Clin Cancer Res, 2017 Jun 21; 23(17). PMID: 28630212    Free PMC article.
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Michal Šmahel.
Int J Mol Sci, 2017 Jun 22; 18(6). PMID: 28635644    Free PMC article.
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.
Qian Zhu, Mu-Yan Cai, +7 authors, Jian-Chuan Xia.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638740    Free PMC article.
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min.
Medicine (Baltimore), 2017 Jun 24; 96(25). PMID: 28640134    Free PMC article.
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Anna Laurell, Maria Lönnemark, +7 authors, Alex Karlsson-Parra.
J Immunother Cancer, 2017 Jun 24; 5. PMID: 28642820    Free PMC article.
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, +12 authors, Terrill K McClanahan.
J Clin Invest, 2017 Jun 27; 127(8). PMID: 28650338    Free PMC article.
Highly Cited.
Immunotherapy biomarkers 2016: overcoming the barriers.
James L Gulley, Jay A Berzofsky, +18 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 Jun 28; 5(1). PMID: 28653584    Free PMC article.
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi.
Nat Rev Clin Oncol, 2017 Jun 28; 14(11). PMID: 28653677    Free PMC article.
Highly Cited. Review.
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Nora Sundahl, Katrien De Wolf, +11 authors, Piet Ost.
J Transl Med, 2017 Jul 01; 15(1). PMID: 28662677    Free PMC article.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, +47 authors, Özlem Türeci.
Nature, 2017 Jul 06; 547(7662). PMID: 28678784
Highly Cited.
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.
Takuya Osada, Michael A Morse, +10 authors, H Kim Lyerly.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680745    Free PMC article.
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.
Julian P Layer, Marie T Kronmüller, +13 authors, Michael Hölzel.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680756    Free PMC article.
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Cristina Belgiovine, Ezia Bello, +10 authors, Maurizio D'Incalci.
Br J Cancer, 2017 Jul 07; 117(5). PMID: 28683469    Free PMC article.
Tracking the T-cell repertoire after adoptive therapy.
Thomas S Watkins, John J Miles.
Clin Transl Immunology, 2017 Jul 12; 6(5). PMID: 28690846    Free PMC article.
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
Y Liu, Y Cheng, +7 authors, C Ma.
Oncogene, 2017 Jul 12; 36(44). PMID: 28692048    Free PMC article.
Highly Cited.
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.
Katharina Maisel, Maria Stella Sasso, Lambert Potin, Melody A Swartz.
Adv Drug Deliv Rev, 2017 Jul 12; 114. PMID: 28694027    Free PMC article.
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.
Karl-Johan Malmberg, Ebba Sohlberg, Jodie P Goodridge, Hans-Gustaf Ljunggren.
Immunogenetics, 2017 Jul 13; 69(8-9). PMID: 28699110    Free PMC article.
Atezolizumab for the treatment of non-small cell lung cancer.
Fernando C Santini, Charles M Rudin.
Expert Rev Clin Pharmacol, 2017 Jul 18; 10(9). PMID: 28714780    Free PMC article.
Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.
Dieke van Dinther, Dorian A Stolk, +3 authors, Joke M M den Haan.
J Leukoc Biol, 2017 Jul 22; 102(4). PMID: 28729358    Free PMC article.
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
Alexandre Reuben, Rachel Gittelman, +37 authors, Jianjun Zhang.
Cancer Discov, 2017 Jul 25; 7(10). PMID: 28733428    Free PMC article.
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Genevieve J Kaunitz, Tricia R Cottrell, +16 authors, Janis M Taube.
Lab Invest, 2017 Jul 25; 97(9). PMID: 28737763    Free PMC article.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells.
Rajeev Kumar, Fang Yu, +6 authors, Jin Xiu.
Onco Targets Ther, 2017 Aug 02; 10. PMID: 28761354    Free PMC article.
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Clemence Granier, Eleonore De Guillebon, +7 authors, Eric Tartour.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761757    Free PMC article.
Highly Cited. Review.
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
Giulia Viale, Dario Trapani, Giuseppe Curigliano.
Biomed Res Int, 2017 Aug 05; 2017. PMID: 28770222    Free PMC article.
Escherichia coli surface display for the selection of nanobodies.
Valencio Salema, Luis Ángel Fernández.
Microb Biotechnol, 2017 Aug 05; 10(6). PMID: 28772027    Free PMC article.
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Hojabr Kakavand, Louise A Jackett, +7 authors, Richard A Scolyer.
Mod Pathol, 2017 Aug 05; 30(12). PMID: 28776578
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(5). PMID: 28777142    Free PMC article.
Highly Cited. Review.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Shona Hendry, Roberto Salgado, +97 authors, Stephen B Fox.
Adv Anat Pathol, 2017 Aug 05; 24(6). PMID: 28777143    Free PMC article.
Highly Cited. Review.
Development of pH-sensitive Dextran Derivatives with Strong Adjuvant Function and Their Application to Antigen Delivery.
Eiji Yuba, Shinya Uesugi, +3 authors, Kenji Kono.
Membranes (Basel), 2017 Aug 05; 7(3). PMID: 28777336    Free PMC article.
Theranostic Gold Nanoantennas for Simultaneous Multiplexed Raman Imaging of Immunomarkers and Photothermal Therapy.
Joseph A Webb, Yu-Chuan Ou, +6 authors, Rizia Bardhan.
ACS Omega, 2017 Aug 07; 2(7). PMID: 28782050    Free PMC article.
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Russell Maxwell, Christopher M Jackson, Michael Lim.
Curr Treat Options Oncol, 2017 Aug 09; 18(8). PMID: 28785997
MSH2 Loss in Primary Prostate Cancer.
Liana B Guedes, Emmanuel S Antonarakis, +12 authors, Tamara L Lotan.
Clin Cancer Res, 2017 Aug 10; 23(22). PMID: 28790115    Free PMC article.
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
François Bertucci, Anthony Gonçalves.
Curr Oncol Rep, 2017 Aug 12; 19(10). PMID: 28799073
Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens.
Clin Cancer Res, 2017 Aug 13; 24(3). PMID: 28801472    Free PMC article.
Highly Cited. Review.
Tumor-derived exosomes induce CD8+ T cell suppressors.
Brian T Maybruck, Lukas W Pfannenstiel, Marcela Diaz-Montero, Brian R Gastman.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28806909    Free PMC article.
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Marian L Burr, Christina E Sparbier, +21 authors, Mark A Dawson.
Nature, 2017 Aug 17; 549(7670). PMID: 28813417    Free PMC article.
Highly Cited.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Sabrina Rossi, Luca Toschi, +3 authors, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2017 Aug 18; 44(13). PMID: 28815334
Immune Modulation Therapy and Imaging: Workshop Report.
Anthony F Shields, Paula M Jacobs, +11 authors, Lalitha K Shankar.
J Nucl Med, 2017 Aug 19; 59(3). PMID: 28818991    Free PMC article.
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Howard Y Li, Maria McSharry, +8 authors, Raphael A Nemenoff.
Cancer Immunol Res, 2017 Aug 19; 5(9). PMID: 28819064    Free PMC article.
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.
Alexandre Reuben, Christine N Spencer, +51 authors, Jennifer A Wargo.
NPJ Genom Med, 2017 Aug 19; 2. PMID: 28819565    Free PMC article.
Highly Cited.
Optimizing tumor immune response through combination of radiation and immunotherapy.
Alissar El Chediak, Ali Shamseddine, +3 authors, Youssef H Zeidan.
Med Oncol, 2017 Aug 23; 34(9). PMID: 28828581
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
K R Kelly, C M Espitia, +6 authors, S T Nawrocki.
Leukemia, 2017 Aug 24; 32(1). PMID: 28832023    Free PMC article.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Rachel M Gibbons Johnson, Haidong Dong.
Front Immunol, 2017 Aug 30; 8. PMID: 28848559    Free PMC article.
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
ESMO Open, 2017 Aug 30; 1(6). PMID: 28848660    Free PMC article.
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
Johan Falkenius, Hemming Johansson, +3 authors, Suzanne Egyhazi Brage.
BMC Cancer, 2017 Aug 31; 17(1). PMID: 28851300    Free PMC article.
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Janice M Mehnert, Arta M Monjazeb, +3 authors, Lyndsay N Harris.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864725    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Immune checkpoint inhibitors in cancer therapy.
Eika S Webb, Peng Liu, +3 authors, Yao-He Wang.
J Biomed Res, 2017 Sep 04; 32(5). PMID: 28866656    Free PMC article.
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.
Joseph P Antonios, Horacio Soto, +11 authors, Robert M Prins.
Proc Natl Acad Sci U S A, 2017 Sep 07; 114(38). PMID: 28874539    Free PMC article.
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, +4 authors, Arun K Iyer.
Front Pharmacol, 2017 Sep 08; 8. PMID: 28878676    Free PMC article.
Highly Cited. Review.
PD1 signal transduction pathways in T cells.
Hugo Arasanz, Maria Gato-Cañas, +4 authors, David Escors.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881701    Free PMC article.
Highly Cited. Review.
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Thomas E Heineman, Adam Widman, Edward C Kuan, Maie St John.
Laryngoscope Investig Otolaryngol, 2017 Sep 13; 2(3). PMID: 28894827    Free PMC article.
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Yu-Pei Chen, Yu Zhang, +9 authors, Jun Ma.
Theranostics, 2017 Sep 16; 7(14). PMID: 28912897    Free PMC article.
Highly Cited.
Emerging biomarkers for cancer immunotherapy in melanoma.
Margaret L Axelrod, Douglas B Johnson, Justin M Balko.
Semin Cancer Biol, 2017 Sep 18; 52(Pt 2). PMID: 28917578    Free PMC article.
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Sulsal Haque, Mahender Yellu, Jaskirat Randhawa, Nooshin Hashemi-Sadraei.
Drug Des Devel Ther, 2017 Sep 19; 11. PMID: 28919706    Free PMC article.
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
Nicolas Jacquelot, Jonathan M Pitt, +5 authors, Laurence Zitvogel.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919986    Free PMC article.
First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.
Denis Migliorini, Nicolas Mach, +6 authors, Pierre-Yves Dietrich.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919999    Free PMC article.
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.
Janne Nestvold, Meng-Yu Wang, +7 authors, Øystein Rekdal.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28920000    Free PMC article.
Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate.
Zhaoxuan Ma, Stephen L Shiao, +6 authors, Arkadiusz Gertych.
Diagn Pathol, 2017 Sep 20; 12(1). PMID: 28923066    Free PMC article.
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Kentaro Inamura, Yusuke Yokouchi, +5 authors, Yuichi Ishikawa.
Cancer Med, 2017 Sep 20; 6(10). PMID: 28925087    Free PMC article.
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Christelle Remy-Ziller, Christine Thioudellet, +8 authors, Karola Rittner.
Hum Vaccin Immunother, 2017 Sep 20; 14(1). PMID: 28925793    Free PMC article.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Fumi Sato-Kaneko, Shiyin Yao, +14 authors, Ezra Ew Cohen.
JCI Insight, 2017 Sep 22; 2(18). PMID: 28931759    Free PMC article.
Highly Cited.
CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.
Fenne L Komdeur, Thalina M Prins, +7 authors, Hans W Nijman.
Oncoimmunology, 2017 Sep 22; 6(9). PMID: 28932636    Free PMC article.
Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
Kyung-Ju Kim, Han Kwang Yang, Woo Ho Kim, Gyeong Hoon Kang.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938605    Free PMC article.
PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.
Qiang Su, Zhigang Sun, +2 authors, Bangwei Cao.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938671    Free PMC article.
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.
Austin K Mattox, Jina Lee, +16 authors, Sara I Pai.
Cancer Res, 2017 Sep 28; 77(22). PMID: 28947422    Free PMC article.
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy.
Els M E Verdegaal, Sjoerd H van der Burg.
Front Immunol, 2017 Sep 30; 8. PMID: 28959257    Free PMC article.
In-vitro effect of pembrolizumab on different T regulatory cell subsets.
S M Toor, A S Syed Khaja, I Alkurd, E Elkord.
Clin Exp Immunol, 2017 Oct 01; 191(2). PMID: 28963773    Free PMC article.
Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy.
Jing Ma, Jianhui Li, +7 authors, Kaichun Wu.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978018    Free PMC article.
The yin and yang of leukotriene B4 mediated inflammation in cancer.
Venkatakrishna R Jala, Sobha R Bodduluri, +3 authors, Bodduluri Haribabu.
Semin Immunol, 2017 Oct 07; 33. PMID: 28982616    Free PMC article.
Impact of sequencing depth and read length on single cell RNA sequencing data of T cells.
Simone Rizzetto, Auda A Eltahla, +5 authors, Fabio Luciani.
Sci Rep, 2017 Oct 08; 7(1). PMID: 28986563    Free PMC article.
Fractional Laser Releases Tumor-Associated Antigens in Poorly Immunogenic Tumor and Induces Systemic Immunity.
Masayoshi Kawakubo, Trevor J Cunningham, Shadmehr Demehri, Dieter Manstein.
Sci Rep, 2017 Oct 08; 7(1). PMID: 28986576    Free PMC article.
Towards a better cancer precision medicine: systems biology meets immunotherapy.
Bhavneet Bhinder, Olivier Elemento.
Curr Opin Syst Biol, 2017 Oct 11; 2. PMID: 28989987    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Jin Wang, Tongxin Xie, +5 authors, Carlos Caulin.
Cancer Prev Res (Phila), 2017 Oct 12; 10(12). PMID: 29018057    Free PMC article.
Antigen receptor repertoire profiling from RNA-seq data.
Dmitriy A Bolotin, Stanislav Poslavsky, +11 authors, Dmitriy M Chudakov.
Nat Biotechnol, 2017 Oct 12; 35(10). PMID: 29020005    Free PMC article.
Highly Cited.
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Raghad M Abdul-Karim, C Lance Cowey.
Cancer Manag Res, 2017 Oct 14; 9. PMID: 29026335    Free PMC article.
CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
Dmitrij Ostroumov, Nora Fekete-Drimusz, +2 authors, Norman Woller.
Cell Mol Life Sci, 2017 Oct 17; 75(4). PMID: 29032503    Free PMC article.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, +22 authors, Timothy A Chan.
Cell, 2017 Oct 17; 171(4). PMID: 29033130    Free PMC article.
Highly Cited.
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials.
Manni Wang, Xuelei Ma, Linghong Guo, Fan Xia.
Drug Des Devel Ther, 2017 Oct 17; 11. PMID: 29033546    Free PMC article.
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Charissa A C Jessurun, Julien A M Vos, Jacqueline Limpens, Rosalie M Luiten.
Front Oncol, 2017 Oct 17; 7. PMID: 29034210    Free PMC article.
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Hye Min Kim, Jinae Lee, Ja Seung Koo.
BMC Cancer, 2017 Oct 19; 17(1). PMID: 29041905    Free PMC article.
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.
Edwin R Parra, Naohiro Uraoka, +7 authors, Jaime Rodriguez-Canales.
Sci Rep, 2017 Oct 19; 7(1). PMID: 29042640    Free PMC article.
Highly Cited.
Tumor-infiltrating CD8+ lymphocytes predict different clinical outcomes in organ- and non-organ-confined urothelial carcinoma of the bladder following radical cystectomy.
Shiqiang Zhang, Jun Wang, Xinyu Zhang, Fangjian Zhou.
PeerJ, 2017 Oct 19; 5. PMID: 29043112    Free PMC article.
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Tamson Moore, Courtney Regan Wagner, +23 authors, Michael I Nishimura.
Cancer Immunol Immunother, 2017 Oct 21; 67(2). PMID: 29052782    Free PMC article.
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Khinh Ranh Voong, Josephine Feliciano, Daniel Becker, Benjamin Levy.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057236    Free PMC article.
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Charles Caldwell, Cory E Johnson, +3 authors, Raghuraman Kannan.
Sci Rep, 2017 Oct 24; 7(1). PMID: 29057919    Free PMC article.
Clinical trials of CAR-T cells in China.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Oct 24; 10(1). PMID: 29058636    Free PMC article.
Highly Cited.
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma.
Ingunn M Stromnes, Ayaka Hulbert, +2 authors, Sunil R Hingorani.
Cancer Immunol Res, 2017 Oct 27; 5(11). PMID: 29066497    Free PMC article.
Highly Cited.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Moshe Sade-Feldman, Yunxin J Jiao, +28 authors, Nir Hacohen.
Nat Commun, 2017 Oct 27; 8(1). PMID: 29070816    Free PMC article.
Highly Cited.
Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases.
Kenji Ina, Ryuichi Furuta, +3 authors, Masahiko Yoneda.
Med Sci (Basel), 2016 Apr 07; 4(2). PMID: 29083372    Free PMC article.
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.
Hilary R Keller, Xin Zhang, +2 authors, James W Wells.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088901    Free PMC article.
Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology.
Dylan H Morris, Katelyn M Gostic, +6 authors, John W McCauley.
Trends Microbiol, 2017 Nov 04; 26(2). PMID: 29097090    Free PMC article.
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
Brendan L Horton, Jason B Williams, +2 authors, Thomas F Gajewski.
Cancer Immunol Res, 2017 Nov 04; 6(1). PMID: 29097422    Free PMC article.
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, +67 authors, J A Wargo.
Science, 2017 Nov 04; 359(6371). PMID: 29097493    Free PMC article.
Highly Cited.
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
NiJiati AiErken, Hui-Juan Shi, +5 authors, Ying Lin.
Int J Biol Sci, 2017 Nov 07; 13(9). PMID: 29104508    Free PMC article.
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Nicholas McGranahan, Rachel Rosenthal, +9 authors, TRACERx Consortium.
Cell, 2017 Nov 07; 171(6). PMID: 29107330    Free PMC article.
Highly Cited.
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer.
Astrid De Meulenaere, Tijl Vermassen, +6 authors, Sylvie Rottey.
Oncotarget, 2017 Nov 09; 8(46). PMID: 29113315    Free PMC article.
New trends in antitumor vaccines in melanoma.
Marcos Vasquez, Shirley Tenesaca, Pedro Berraondo.
Ann Transl Med, 2017 Nov 09; 5(19). PMID: 29114542    Free PMC article.
Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).
Enrique Espinosa, Ivan Márquez-Rodas, +5 authors, Spanish Melanoma Group (GEM).
Ann Transl Med, 2017 Nov 09; 5(19). PMID: 29114547    Free PMC article.
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
Justin M David, Charli Dominguez, +3 authors, Claudia Palena.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123964    Free PMC article.
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.
Kazuaki Okamura, Yuichi Fukuda, +8 authors, Hiroshi Mukae.
Thorac Cancer, 2017 Nov 14; 9(1). PMID: 29131510    Free PMC article.
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
Marta Łuksza, Nadeem Riaz, +9 authors, Benjamin D Greenbaum.
Nature, 2017 Nov 14; 551(7681). PMID: 29132144    Free PMC article.
Highly Cited.
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Vinod P Balachandran, Marta Łuksza, +56 authors, Steven D Leach.
Nature, 2017 Nov 14; 551(7681). PMID: 29132146    Free PMC article.
Highly Cited.
Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.
Shay Warren, Meenal Kheterpal, +3 authors, Melissa P Pulitzer.
J Am Acad Dermatol, 2017 Nov 15; 78(3). PMID: 29132694    Free PMC article.
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.
Jinkai Teo, Anja Mirenska, +9 authors, David Ag Skibinski.
Future Sci OA, 2017 Nov 15; 3(4). PMID: 29134128    Free PMC article.
Genetic and immune features of resectable malignant brainstem gliomas.
Yang Zhang, Changcun Pan, +4 authors, Liwei Zhang.
Oncotarget, 2017 Nov 16; 8(47). PMID: 29137285    Free PMC article.
Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.
Keita Aoto, Kousaku Mimura, +10 authors, Koji Kono.
Oncol Rep, 2017 Nov 16; 39(1). PMID: 29138861    Free PMC article.
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
L Buisseret, S Pommey, +13 authors, J Stagg.
Ann Oncol, 2017 Nov 18; 29(4). PMID: 29145561    Free PMC article.
Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
Minan Wang, Li-Chin Yao, +14 authors, James G Keck.
FASEB J, 2017 Nov 18; 32(3). PMID: 29146734    Free PMC article.
Highly Cited.
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Carole Fournier, François Martin, +3 authors, Lionel Apetoh.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147628    Free PMC article.
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2017 Nov 22; 5(4). PMID: 29156643    Free PMC article.
PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Yoon Jin Cha, Hyo Sup Shim.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163763    Free PMC article.
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
Gloria Mittica, Eleonora Ghisoni, +3 authors, Giorgio Valabrega.
Oncotarget, 2017 Nov 23; 8(52). PMID: 29163851    Free PMC article.
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
W Robert Liu, Margaret A Shipp.
Blood, 2017 Nov 24; 130(21). PMID: 29167175    Free PMC article.
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.
Allan Ramos-Esquivel, Alicia van der Laat, +2 authors, Luis Corrales-Rodríguez.
ESMO Open, 2017 Nov 29; 2(3). PMID: 29181191    Free PMC article.
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.
Thomas Hecking, Thore Thiesler, +10 authors, Kirsten Kübler.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190964    Free PMC article.
Implications of the tumor immune microenvironment for staging and therapeutics.
Janis M Taube, Jérôme Galon, +8 authors, Ashley Cimino-Mathews.
Mod Pathol, 2017 Dec 02; 31(2). PMID: 29192647    Free PMC article.
Highly Cited. Review.
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Michael J Topper, Michelle Vaz, +15 authors, Stephen B Baylin.
Cell, 2017 Dec 02; 171(6). PMID: 29195073    Free PMC article.
Highly Cited.
Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.
Yang Du, Ting Sun, +5 authors, Jie Tian.
Int J Nanomedicine, 2017 Dec 05; 12. PMID: 29200846    Free PMC article.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Franz Villarroel-Espindola, Xiaoqing Yu, +9 authors, Kurt A Schalper.
Clin Cancer Res, 2017 Dec 06; 24(7). PMID: 29203588    Free PMC article.
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Ryuma Tokunaga, Wu Zhang, +6 authors, Heinz-Josef Lenz.
Cancer Treat Rev, 2017 Dec 06; 63. PMID: 29207310    Free PMC article.
Highly Cited. Review.
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Anna C Filley, Mario Henriquez, Mahua Dey.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207684    Free PMC article.
Highly Cited. Review.
Excellent response to chemotherapy post immunotherapy.
Ashish D Dwary, Samip Master, +8 authors, Kavitha Beedupalli.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207685    Free PMC article.
Rho GTPase effectors and NAD metabolism in cancer immune suppression.
Mahmoud Chaker, Audrey Minden, +4 authors, Asfar S Azmi.
Expert Opin Ther Targets, 2017 Dec 07; 22(1). PMID: 29207896    Free PMC article.
Program Cell Death Receptor-1-Mediated Invariant Natural Killer T-Cell Control of Peritoneal Macrophage Modulates Survival in Neonatal Sepsis.
Eleanor A Fallon, Tristen T Chun, +3 authors, Daithi S Heffernan.
Front Immunol, 2017 Dec 07; 8. PMID: 29209308    Free PMC article.
Heterogeneity of colon cancer: from bench to bedside.
Marco C Merlano, Cristina Granetto, +2 authors, Ornella Garrone.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209524    Free PMC article.
Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival.
Kai-Wen Huang, Po-Huang Lee, +3 authors, Nagy Habib.
Oncotarget, 2017 Dec 08; 8(55). PMID: 29212179    Free PMC article.
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Diego Chowell, Luc G T Morris, +17 authors, Timothy A Chan.
Science, 2017 Dec 09; 359(6375). PMID: 29217585    Free PMC article.
Highly Cited.
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
W Robert Liu, Margaret A Shipp.
Hematology Am Soc Hematol Educ Program, 2017 Dec 10; 2017(1). PMID: 29222272    Free PMC article.
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Chan-Young Ock, Sehui Kim, +12 authors, Dae Seog Heo.
Oncotarget, 2017 Dec 13; 8(58). PMID: 29228662    Free PMC article.
Immunotherapy in ovarian cancer.
K Odunsi.
Ann Oncol, 2017 Dec 13; 28(suppl_8). PMID: 29232467    Free PMC article.
p16Ink4a and p21Cip1/Waf1 promote tumour growth by enhancing myeloid-derived suppressor cells chemotaxis.
Atsushi Okuma, Aki Hanyu, Sugiko Watanabe, Eiji Hara.
Nat Commun, 2017 Dec 14; 8(1). PMID: 29234059    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
Xiaoli Ju, Rong Shen, +4 authors, Miao Chen.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245908    Free PMC article.
PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
Fang Zheng, Jianzhong Dang, +3 authors, Fanjun Cheng.
Biomed Res Int, 2017 Dec 19; 2017. PMID: 29250533    Free PMC article.
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade.
Feng Wang, Qian Yin, Liang Chen, Mark M Davis.
Proc Natl Acad Sci U S A, 2017 Dec 20; 115(1). PMID: 29255057    Free PMC article.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Claire Lhuillier, Claire Vanpouille-Box, +2 authors, Sandra Demaria.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258856    Free PMC article.
Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.
Lokesh Agrawal, Kelly B Engel, Sarah R Greytak, Helen M Moore.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258857    Free PMC article.
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.
Wen-Ying Zhang, Yao Wang, +12 authors, Wei-Dong Han.
Signal Transduct Target Ther, 2016 Mar 11; 1. PMID: 29263894    Free PMC article.
The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy.
Zhiwei Hu.
J Thorac Dis, 2017 Dec 23; 9(11). PMID: 29268478    Free PMC article.
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Florie Bertrand, Anne Montfort, +9 authors, Bruno Ségui.
Nat Commun, 2017 Dec 24; 8(1). PMID: 29273790    Free PMC article.
Highly Cited.
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
R Colomer, I Aranda-López, +7 authors, J Palacios-Calvo.
Clin Transl Oncol, 2017 Dec 24; 20(7). PMID: 29273958    Free PMC article.
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.
Michael Peled, Anna S Tocheva, +10 authors, Adam Mor.
Proc Natl Acad Sci U S A, 2017 Dec 29; 115(3). PMID: 29282323    Free PMC article.
Predictors of response and resistance to checkpoint inhibitors in solid tumors.
Sanjana V Rao, Amy E Moran, Julie N Graff.
Ann Transl Med, 2017 Dec 30; 5(23). PMID: 29285501    Free PMC article.
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Sylvain Simon, Nathalie Labarriere.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296515    Free PMC article.
Highly Cited. Review.
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.
Xiang Yan, Li Wang, +11 authors, Bingliang Fang.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296537    Free PMC article.
Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.
A Kunert, M Chmielewski, +3 authors, R Debets.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296541    Free PMC article.
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Natalie A Bezman, Amy Jhatakia, +9 authors, Robert F Graziano.
Blood Adv, 2018 Jan 04; 1(12). PMID: 29296719    Free PMC article.
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.
Christopher R Bolen, Ronald McCord, +10 authors, Jeffrey M Venstrom.
Blood Adv, 2018 Jan 04; 1(22). PMID: 29296835    Free PMC article.
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Adel Samson, Karen J Scott, +36 authors, Alan A Melcher.
Sci Transl Med, 2018 Jan 05; 10(422). PMID: 29298869    Free PMC article.
Highly Cited.
Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions.
Vinit Shanbhag, Shrikesh Sachdev, +2 authors, Kamalendra Singh.
Biology (Basel), 2018 Jan 06; 7(1). PMID: 29301327    Free PMC article.
A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma.
Fred T Valentine, Frederick M Golomb, Matthew Harris, Daniel F Roses.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308310    Free PMC article.
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Marie Kostine, Inge H Briaire-de Bruijn, +9 authors, Judith V M G Bovée.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308311    Free PMC article.
Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.
Marco Tucci, Anna Passarelli, +6 authors, Francesco Silvestris.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308314    Free PMC article.
Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa.
Yichen Chen, Qiusheng Li, +9 authors, Zhi Wang.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308315    Free PMC article.
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.
Laura Rivino, Nina Le Bert, +13 authors, Antonio Bertoletti.
J Clin Invest, 2018 Jan 09; 128(2). PMID: 29309050    Free PMC article.
Highly Cited.
Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials.
Wei Wei, Zhibin Luo.
Medicine (Baltimore), 2018 Jan 10; 96(48). PMID: 29310385    Free PMC article.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
Martin W LaFleur, Yuki Muroyama, Charles G Drake, Arlene H Sharpe.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311378    Free PMC article.
Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy.
Misako Matsumoto, Yohei Takeda, Megumi Tatematsu, Tsukasa Seya.
Front Immunol, 2018 Jan 10; 8. PMID: 29312355    Free PMC article.
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.
Álvaro de Mingo Pulido, Alycia Gardner, +5 authors, Brian Ruffell.
Cancer Cell, 2018 Jan 10; 33(1). PMID: 29316433    Free PMC article.
Highly Cited.
High response rate to PD-1 blockade in desmoplastic melanomas.
Zeynep Eroglu, Jesse M Zaretsky, +22 authors, Antoni Ribas.
Nature, 2018 Jan 11; 553(7688). PMID: 29320474    Free PMC article.
Highly Cited.
CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
James Ziai, Houston N Gilbert, +4 authors, Jeong M Kim.
PLoS One, 2018 Jan 11; 13(1). PMID: 29320521    Free PMC article.
Impact of oncogenic pathways on evasion of antitumour immune responses.
Stefani Spranger, Thomas F Gajewski.
Nat Rev Cancer, 2018 Jan 13; 18(3). PMID: 29326431    Free PMC article.
Highly Cited. Review.
Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
Lindsay K Ward-Kavanagh, Kathleen M Kokolus, +2 authors, Todd D Schell.
Cancer Immunol Immunother, 2018 Jan 15; 67(4). PMID: 29332158    Free PMC article.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Masoud F Tavazoie, Ilana Pollack, +21 authors, Sohail F Tavazoie.
Cell, 2018 Jan 18; 172(4). PMID: 29336888    Free PMC article.
Highly Cited.
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Haidong Tang, Yong Liang, +18 authors, Yang-Xin Fu.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337303    Free PMC article.
Highly Cited.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Heng Lin, Shuang Wei, +16 authors, Weiping Zou.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337305    Free PMC article.
Highly Cited.
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.
Dewan Md Sakib Hossain, Sarah Javaid, +8 authors, Alissa Chackerian.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337311    Free PMC article.
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Hira Rizvi, Francisco Sanchez-Vega, +29 authors, Matthew D Hellmann.
J Clin Oncol, 2018 Jan 18; 36(7). PMID: 29337640    Free PMC article.
Highly Cited.
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Charlotte E Ariyan, Mary Sue Brady, +19 authors, James P Allison.
Cancer Immunol Res, 2018 Jan 18; 6(2). PMID: 29339377    Free PMC article.
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.
Emanuela Palmerini, Claudio Agostinelli, +7 authors, Stefano Ferrari.
Oncotarget, 2018 Jan 18; 8(67). PMID: 29340095    Free PMC article.
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc, Julien Adam, +15 authors, Sophie Postel-Vinay.
ESMO Open, 2018 Jan 19; 3(1). PMID: 29344407    Free PMC article.
Profiling Tumor Infiltrating Immune Cells with CIBERSORT.
Binbin Chen, Michael S Khodadoust, +2 authors, Ash A Alizadeh.
Methods Mol Biol, 2018 Jan 19; 1711. PMID: 29344893    Free PMC article.
Highly Cited.
Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.
Nataša Obermajer, Julie Urban, +4 authors, Pawel Kalinski.
Nat Protoc, 2018 Jan 19; 13(2). PMID: 29345636
Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Akihiro Hosoi, Kazuyoshi Takeda, +10 authors, Kazuhiro Kakimi.
Sci Rep, 2018 Jan 20; 8(1). PMID: 29348598    Free PMC article.
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Davis A Witt, Andrew M Donson, +9 authors, Andrea M Griesinger.
Pediatr Blood Cancer, 2018 Jan 20; 65(5). PMID: 29350470    Free PMC article.
Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.
Stefania Bellone, Natalia Buza, +8 authors, Alessandro D Santin.
Clin Cancer Res, 2018 Jan 21; 24(14). PMID: 29351920    Free PMC article.
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.
Tricia R Cottrell, Janis M Taube.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360727    Free PMC article.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Theodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360728    Free PMC article.
Highly Cited. Review.
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Haa-Na Song, Min Gyu Kang, +4 authors, Gyeong-Won Lee.
Cancer Res Treat, 2018 Jan 25; 50(4). PMID: 29361819    Free PMC article.
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.
Petar Jelinic, Jacob Ricca, +4 authors, Dmitriy Zamarin.
J Natl Cancer Inst, 2018 Jan 25; 110(7). PMID: 29365144    Free PMC article.
Highly Cited.
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Jason Zhu, Andrew J Armstrong, +4 authors, Tian Zhang.
J Immunother Cancer, 2018 Jan 26; 6(1). PMID: 29368638    Free PMC article.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P D'Angelo, Michelle R Mahoney, +8 authors, Howard Streicher.
Lancet Oncol, 2018 Jan 27; 19(3). PMID: 29370992    Free PMC article.
Highly Cited.
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Amy L Cummings, Edward B Garon.
Cancer Biol Med, 2018 Jan 27; 14(4). PMID: 29372100    Free PMC article.
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Priya Srinivasan, Xiaofang Wu, +2 authors, Anthony D Sandler.
PLoS Med, 2018 Jan 30; 15(1). PMID: 29377881    Free PMC article.
Variability of PD-L1 expression in mastocytosis.
Ellen W Hatch, Mary Beth Geeze, +11 authors, Tracy I George.
Blood Adv, 2018 Jan 31; 2(3). PMID: 29378725    Free PMC article.
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Niki Karachaliou, Maria Gonzalez-Cao, +15 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383037    Free PMC article.
Highly Cited.
Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors.
Jeremy M Grenier, Stephen T Yeung, +2 authors, Kamal M Khanna.
Front Immunol, 2018 Feb 02; 8. PMID: 29387061    Free PMC article.
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Anton Uryvaev, Maria Passhak, +2 authors, Gil Bar-Sela.
Med Oncol, 2018 Feb 02; 35(3). PMID: 29388007
Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.
Alessandra Cesano, Sarah Warren.
Biomedicines, 2018 Feb 03; 6(1). PMID: 29393888    Free PMC article.
Highly Cited. Review.
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Margaretha G M Roemer, Robert A Redd, +26 authors, Margaret A Shipp.
J Clin Oncol, 2018 Feb 03; 36(10). PMID: 29394125    Free PMC article.
Highly Cited.
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
Xiaofang Xing, Jianping Guo, +23 authors, Jiafu Ji.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399387    Free PMC article.
Highly Cited.
PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Melanie Boxberg, Katja Steiger, +6 authors, Katja Specht.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399389    Free PMC article.
Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.
Jeroen F Vermeulen, Wim Van Hecke, +8 authors, Niels Bovenschen.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399402    Free PMC article.
Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.
Jorrit De Waele, Elly Marcq, +14 authors, Evelien Lj Smits.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399410    Free PMC article.
Predictive immune biomarkers: an unattainable chimera?
Anna Maria Trotta, Roberto Pacelli, Stefania Scala.
Cell Mol Immunol, 2018 Feb 06; 15(8). PMID: 29400708    Free PMC article.
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami-Chouaib.
Front Immunol, 2018 Feb 07; 9. PMID: 29403496    Free PMC article.
Highly Cited. Review.
Emerging Biomarkers in Cutaneous Melanoma.
Anna Eisenstein, Estela Chen Gonzalez, +6 authors, Rhoda M Alani.
Mol Diagn Ther, 2018 Feb 08; 22(2). PMID: 29411301
Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model.
Shengbin Shi, Quan Rao, +3 authors, Zuoxing Niu.
Transl Oncol, 2018 Feb 08; 11(2). PMID: 29413757    Free PMC article.
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Manjima Dhar, Jessica Wong, +8 authors, Rajan P Kulkarni.
Sci Rep, 2018 Feb 09; 8(1). PMID: 29416054    Free PMC article.
Dendritic cells loaded with tumor derived exosomes for cancer immunotherapy.
Hongyu Liu, Ling Chen, +8 authors, Tianyi Liu.
Oncotarget, 2018 Feb 09; 9(2). PMID: 29416821    Free PMC article.
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Francisco Perea, Abel Sánchez-Palencia, +9 authors, Natalia Aptsiauri.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423109    Free PMC article.
Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.
Curtis J Perry, Andrés R Muñoz-Rojas, +11 authors, Susan M Kaech.
J Exp Med, 2018 Feb 14; 215(3). PMID: 29436395    Free PMC article.
Highly Cited.
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.
Sabine Hoves, Chia-Huey Ooi, +15 authors, Carola H Ries.
J Exp Med, 2018 Feb 14; 215(3). PMID: 29436396    Free PMC article.
Highly Cited.
DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis.
Sharon K Kuss-Duerkop, Joseph A Westrich, Dohun Pyeon.
Viruses, 2018 Feb 14; 10(2). PMID: 29438328    Free PMC article.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Sanjeev Mariathasan, Shannon J Turley, +39 authors, Thomas Powles.
Nature, 2018 Feb 15; 554(7693). PMID: 29443960    Free PMC article.
Highly Cited.
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Amanda J Oliver, Peter K H Lau, +4 authors, Clare Y Slaney.
Front Immunol, 2018 Feb 16; 9. PMID: 29445373    Free PMC article.
The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
Tatsunori Kiriu, Masatsugu Yamamoto, +7 authors, Yoshihiro Nishimura.
PLoS One, 2018 Feb 16; 13(2). PMID: 29447258    Free PMC article.
Highly Cited. Review.
Engineering chimeric antigen receptor-T cells for cancer treatment.
Baixin Ye, Creed M Stary, +3 authors, Xiaoxing Xiong.
Mol Cancer, 2018 Feb 17; 17(1). PMID: 29448937    Free PMC article.
PD-L1 expression in inflammatory myofibroblastic tumors.
Tricia R Cottrell, Anh T Duong, +4 authors, Deborah A Belchis.
Mod Pathol, 2018 Feb 17; 31(7). PMID: 29449680    Free PMC article.
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.
Xin Hong, Ryan J Sullivan, +20 authors, Daniel A Haber.
Proc Natl Acad Sci U S A, 2018 Feb 18; 115(10). PMID: 29453278    Free PMC article.
Highly Cited.
Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.
Elizabeth A Mills, Yang Mao-Draayer.
Front Immunol, 2018 Feb 20; 9. PMID: 29456537    Free PMC article.
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Michael Dougan, Jessica R Ingram, +12 authors, Stephanie K Dougan.
Cancer Immunol Res, 2018 Feb 21; 6(4). PMID: 29459478    Free PMC article.
Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
Robyn D Gartrell, Douglas K Marks, +19 authors, Yvonne M Saenger.
Cancer Immunol Res, 2018 Feb 23; 6(4). PMID: 29467127    Free PMC article.
Highly Cited.
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Samuel Rosner, Erica Kwong, +9 authors, Michael A Postow.
Cancer Med, 2018 Feb 23; 7(3). PMID: 29468834    Free PMC article.
Highly Cited.
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Yared Hailemichael, Amber Woods, +17 authors, Willem W Overwijk.
J Clin Invest, 2018 Feb 27; 128(4). PMID: 29480817    Free PMC article.
Highly Cited.
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Antje Tunger, Maximilian Kießler, +4 authors, Marc Schmitz.
Biomedicines, 2018 Mar 02; 6(1). PMID: 29494517    Free PMC article.
Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma.
Daniel Xia, Ruben Casanova, +4 authors, Alex Soltermann.
Sci Rep, 2018 Mar 04; 8(1). PMID: 29500362    Free PMC article.
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Dmitriy Zamarin, Jacob M Ricca, +7 authors, Jedd D Wolchok.
J Clin Invest, 2018 Mar 06; 128(4). PMID: 29504948    Free PMC article.
Highly Cited.
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Shannon Coy, Rumana Rashid, +9 authors, Sandro Santagata.
Neuro Oncol, 2018 Mar 07; 20(8). PMID: 29509940    Free PMC article.
Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
Denis R Beckford Vera, Christof C Smith, +7 authors, Matthew C Parrott.
PLoS One, 2018 Mar 08; 13(3). PMID: 29513764    Free PMC article.
The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.
Constantinos Roufas, Dimitrios Chasiotis, +3 authors, Apostolos Zaravinos.
Front Oncol, 2018 Mar 09; 8. PMID: 29515971    Free PMC article.
Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.
Xianda Zhao, Audre May, Emil Lou, Subbaya Subramanian.
Transl Res, 2018 Mar 09; 196. PMID: 29518351    Free PMC article.
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
Kendra C Foley, Michael I Nishimura, Tamson V Moore.
Melanoma Res, 2018 Mar 10; 28(3). PMID: 29521881    Free PMC article.
Is it time to change our vision of tumor metabolism prior to immunotherapy?
Fabio Grizzi, Angelo Castello, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2018 Mar 14; 45(6). PMID: 29532102
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Christian D Fankhauser, Peter J Schüffler, +8 authors, Peter J Wild.
Oncotarget, 2018 Mar 15; 9(12). PMID: 29535806    Free PMC article.
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Kentaro Inamura.
Cancers (Basel), 2018 Mar 15; 10(3). PMID: 29538329    Free PMC article.
Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.
Taigo Kato, Tatsuo Matsuda, +10 authors, Yusuke Nakamura.
Oncotarget, 2018 Mar 16; 9(13). PMID: 29541393    Free PMC article.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
Current status and perspectives in immunotherapy for metastatic melanoma.
Riccardo Marconcini, Francesco Spagnolo, +13 authors, Italian Melanoma Intergroup (IMI).
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552325    Free PMC article.
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells.
Clémence Granier, Emeline Vinatier, +14 authors, Éric Tartour.
J Vis Exp, 2018 Mar 20; (132). PMID: 29553498    Free PMC article.
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Gao Zhang, Lawrence W Wu, +41 authors, Jerry W Shay.
Clin Cancer Res, 2018 Mar 23; 24(19). PMID: 29563139    Free PMC article.
Fusobacterium nucleatum and colorectal cancer: A review.
Fu-Mei Shang, Hong-Li Liu.
World J Gastrointest Oncol, 2018 Mar 23; 10(3). PMID: 29564037    Free PMC article.
Highly Cited. Review.
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations.
Jesse J Salk, Michael W Schmitt, Lawrence A Loeb.
Nat Rev Genet, 2018 Mar 27; 19(5). PMID: 29576615    Free PMC article.
Highly Cited. Review.
Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.
Melissa A Meyer, John M Baer, +12 authors, David G DeNardo.
Nat Commun, 2018 Mar 30; 9(1). PMID: 29593283    Free PMC article.
Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.
Yohei Takeda, Masahiro Azuma, +3 authors, Tsukasa Seya.
Front Immunol, 2018 Mar 30; 9. PMID: 29593736    Free PMC article.
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Maarten Versteven, Johan M J Van den Bergh, +4 authors, Eva Lion.
Front Immunol, 2018 Mar 31; 9. PMID: 29599770    Free PMC article.
Highly Cited. Review.
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Koji Takada, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
J Transl Med, 2018 Apr 05; 16(1). PMID: 29615076    Free PMC article.
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers.
Daniel J McGrail, Lorenzo Federico, +6 authors, Nidhi Sahni.
Nat Commun, 2018 Apr 05; 9(1). PMID: 29615613    Free PMC article.
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
Jianmin Zhu, Jin-Qing Liu, +11 authors, Xue-Feng Bai.
JCI Insight, 2018 Apr 06; 3(7). PMID: 29618655    Free PMC article.
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
John M Wrangle, Vamsidhar Velcheti, +26 authors, Mark P Rubinstein.
Lancet Oncol, 2018 Apr 10; 19(5). PMID: 29628312    Free PMC article.
Highly Cited.
Novel Systemic Therapies for Advanced Gastric Cancer.
Hong Jun Kim, Sang Cheul Oh.
J Gastric Cancer, 2018 Apr 10; 18(1). PMID: 29629216    Free PMC article.
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.
Shisuo Du, Neal McCall, +6 authors, Bo Lu.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632720    Free PMC article.
The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.
Lorea Villanueva, Leyre Silva, +9 authors, Pablo Sarobe.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632721    Free PMC article.
Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction.
Manja Idorn, Maria Olsen, +6 authors, Per Thor Straten.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632724    Free PMC article.
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Chang-Long Chen, Qiu-Zhong Pan, +17 authors, Jian-Chuan Xia.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632736    Free PMC article.
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Natalie J Neubert, Martina Schmittnaegel, +18 authors, Daniel E Speiser.
Sci Transl Med, 2018 Apr 13; 10(436). PMID: 29643229    Free PMC article.
Highly Cited.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, +32 authors, Drew M Pardoll.
N Engl J Med, 2018 Apr 17; 378(21). PMID: 29658848    Free PMC article.
Highly Cited.
Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma.
Cheng Xu, Zhi-Hong Zhang.
Chin Med J (Engl), 2018 Apr 18; 131(8). PMID: 29664061    Free PMC article.
A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells.
Jolien J Luimstra, Malgorzata A Garstka, +7 authors, Huib Ovaa.
J Exp Med, 2018 Apr 19; 215(5). PMID: 29666167    Free PMC article.
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
Dean A Fennell, Emma Kirkpatrick, +13 authors, Gareth Griffiths.
Trials, 2018 Apr 20; 19(1). PMID: 29669604    Free PMC article.
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Yiyi Yan, Siyu Cao, +12 authors, Haidong Dong.
JCI Insight, 2018 Apr 20; 3(8). PMID: 29669928    Free PMC article.
Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
Nataliya Rohr-Udilova, Florian Klinglmüller, +11 authors, Michael Trauner.
Sci Rep, 2018 Apr 20; 8(1). PMID: 29670256    Free PMC article.
Highly Cited.
Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Lei Wang, Qiongyan Zhang, +4 authors, Weiqi Sheng.
Cancer Med, 2018 Apr 20; 7(6). PMID: 29673110    Free PMC article.
Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy.
Jonathan F Anker, Anum F Naseem, +3 authors, Praveen Thumbikat.
Nat Commun, 2018 Apr 25; 9(1). PMID: 29686284    Free PMC article.
CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
Chenlu Zhang, Zhi Li, +9 authors, Yunpeng Liu.
BMC Cancer, 2018 Apr 25; 18(1). PMID: 29690901    Free PMC article.
The opposing roles of CD4+ T cells in anti-tumour immunity.
Tomasz Ahrends, Jannie Borst.
Immunology, 2018 Apr 28;. PMID: 29700809    Free PMC article.
Integrative Pharmacology: Advancing Development of Effective Immunotherapies.
Mohammad Tabrizi, Daping Zhang, Vaishnavi Ganti, Glareh Azadi.
AAPS J, 2018 Apr 29; 20(4). PMID: 29704129
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Cesar August Santa-Maria, Taigo Kato, +14 authors, Francis J Giles.
Oncotarget, 2018 May 04; 9(27). PMID: 29721177    Free PMC article.
Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.
Neil L Berinstein, Michael McNamara, +2 authors, Gregory T Wolf.
Oncoimmunology, 2018 May 04; 7(5). PMID: 29721379    Free PMC article.
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.
Breann C Sommer, Deepika Dhawan, Timothy L Ratliff, Deborah W Knapp.
Bladder Cancer, 2018 May 08; 4(2). PMID: 29732386    Free PMC article.
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Ailin Li, Hampartsoum B Barsoumian, +10 authors, James W Welsh.
Cancer Lett, 2018 May 11; 431. PMID: 29746927    Free PMC article.
Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.
Hui-Shan Huang, Harvey Yu-Li Su, +4 authors, Meng-Che Hsieh.
Sci Rep, 2018 May 12; 8(1). PMID: 29748589    Free PMC article.
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.
Wei Xiao, John D Klement, +2 authors, Kebin Liu.
J Immunol, 2018 May 13; 201(1). PMID: 29752314    Free PMC article.
Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Brett J Hos, Elena Tondini, Sander I van Kasteren, Ferry Ossendorp.
Front Immunol, 2018 May 15; 9. PMID: 29755468    Free PMC article.
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Ioannis Zerdes, Alexios Matikas, +2 authors, Theodoros Foukakis.
Oncogene, 2018 May 17; 37(34). PMID: 29765155    Free PMC article.
Highly Cited. Review.
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, +66 authors, John V Heymach.
Cancer Discov, 2018 May 19; 8(7). PMID: 29773717    Free PMC article.
Highly Cited.
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.
Miles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer A Wargo.
Front Immunol, 2018 May 22; 9. PMID: 29780391    Free PMC article.
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Sharareh Niknam, Hampartsoum B Barsoumian, +15 authors, James W Welsh.
Clin Cancer Res, 2018 May 23; 24(22). PMID: 29784675    Free PMC article.
The era of immunogenomics/immunopharmacogenomics.
Makda Zewde, Kazuma Kiyotani, +13 authors, Yusuke Nakamura.
J Hum Genet, 2018 May 23; 63(8). PMID: 29785006
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Haiyue Wang, Zhongwu Li, +7 authors, Dongmei Lin.
Diagn Pathol, 2018 May 24; 13(1). PMID: 29789013    Free PMC article.
Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Yohei Takeda, Sumito Yoshida, +4 authors, Misako Matsumoto.
Cancer Sci, 2018 May 24; 109(7). PMID: 29791768    Free PMC article.
In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.
Abner A Murray, Chao Wang, Steven Fiering, Nicole F Steinmetz.
Mol Pharm, 2018 May 26; 15(9). PMID: 29798673    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.
Jeremy M O'Connor, Kristen L Fessele, +10 authors, Cary P Gross.
JAMA Oncol, 2018 May 26; 4(8). PMID: 29800974    Free PMC article.
Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
Richard Kim, Domenico Coppola, +4 authors, Dae Won Kim.
Oncotarget, 2018 May 29; 9(34). PMID: 29805739    Free PMC article.
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.
Ari J Rosenberg, Derek A Wainwright, +12 authors, Victoria M Villaflor.
Oncotarget, 2018 May 29; 9(34). PMID: 29805749    Free PMC article.
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, +7 authors, Patrick J Stiff.
J Ovarian Res, 2018 May 31; 11(1). PMID: 29843813    Free PMC article.
Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.
Anne Sophie Kubasch, Rebekka Wehner, +9 authors, Uwe Platzbecker.
Blood Adv, 2018 May 31; 2(11). PMID: 29844203    Free PMC article.
Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.
Yonghua Wang, Jing Liu, +6 authors, Haitao Niu.
Onco Targets Ther, 2018 May 31; 11. PMID: 29844686    Free PMC article.
Immunotherapeutic interventions of Triple Negative Breast Cancer.
Zehuan Li, Yiran Qiu, +2 authors, Jin Wang.
J Transl Med, 2018 Jun 01; 16(1). PMID: 29848327    Free PMC article.
PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Haiyan Tai, Qin Yang, +7 authors, Congjian Xu.
J Immunol Res, 2018 Jun 02; 2018. PMID: 29854854    Free PMC article.
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Ying Dai, Chengdu Sun, +2 authors, Bo Zhu.
J Cell Mol Med, 2018 Jun 02; 22(8). PMID: 29855141    Free PMC article.
Immunotherapy and Prevention of Pancreatic Cancer.
Alexander H Morrison, Katelyn T Byrne, Robert H Vonderheide.
Trends Cancer, 2018 Jun 05; 4(6). PMID: 29860986    Free PMC article.
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.
Guillaume Herbreteau, Audrey Vallée, +6 authors, Marc G Denis.
Oncotarget, 2018 Jun 05; 9(38). PMID: 29861869    Free PMC article.
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.
Le Ying, Feng Yan, +13 authors, Yiqun Hu.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872566    Free PMC article.
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
Magalie Dosset, Thaiz Rivera Vargas, +13 authors, Lionel Apetoh.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872568    Free PMC article.
Highly Cited.
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Zenghui Qian, Yiming Li, +4 authors, Xing Liu.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872572    Free PMC article.
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.
Dagmar Kollmann, Desislava Ignatova, +13 authors, Sebastian F Schoppmann.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872575    Free PMC article.
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Na Luo, Luigi Formisano, +8 authors, Justin M Balko.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872580    Free PMC article.
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment.
Fathima Zumla Cader, Ron C J Schackmann, +14 authors, Margaret A Shipp.
Blood, 2018 Jun 09; 132(8). PMID: 29880615    Free PMC article.
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Yasunori Akutsu, Kentaro Murakami, +8 authors, Hisahiro Matsubara.
Esophagus, 2018 Jun 13; 15(2). PMID: 29892935
Melanoma Immunotherapy: Next-Generation Biomarkers.
Sabrina A Hogan, Mitchell P Levesque, Phil F Cheng.
Front Oncol, 2018 Jun 14; 8. PMID: 29896449    Free PMC article.
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
David Wang, Jason Quiros, +12 authors, Michel DuPage.
Cell Rep, 2018 Jun 14; 23(11). PMID: 29898397    Free PMC article.
Highly Cited.
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
Arnav Mehta, Yeon Joo Kim, +8 authors, Antoni Ribas.
Cancer Discov, 2018 Jun 15; 8(8). PMID: 29899062    Free PMC article.
Highly Cited.
TGFβ shuts the door on T cells.
Tobias Bald, Mark J Smyth.
Br J Cancer, 2018 Jun 15; 119(1). PMID: 29899392    Free PMC article.
Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin.
Jessica J O'Konek, Elena Ambrosino, +5 authors, Jay A Berzofsky.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900040    Free PMC article.
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.
Tsuyoshi Hamada, Thing Rinda Soong, +28 authors, Shuji Ogino.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900052    Free PMC article.
Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy.
Kaiyuan Ni, Guangxu Lan, +7 authors, Wenbin Lin.
Nat Commun, 2018 Jun 17; 9(1). PMID: 29907739    Free PMC article.
Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
Robert W Wilkinson, Andrew J Leishman.
Front Immunol, 2018 Jun 19; 9. PMID: 29910800    Free PMC article.
The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.
Nicholas Meti, Khashayar Esfahani, Nathalie A Johnson.
Cancers (Basel), 2018 Jun 20; 10(6). PMID: 29914088    Free PMC article.
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Chao-Qun Liu, Jing Xu, +7 authors, Limin Zheng.
Br J Cancer, 2018 Jun 21; 119(1). PMID: 29921949    Free PMC article.
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Patrick Danaher, Sarah Warren, +6 authors, Alessandra Cesano.
J Immunother Cancer, 2018 Jun 23; 6(1). PMID: 29929551    Free PMC article.
Highly Cited.
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Qiao Wang, Fan Feng, +7 authors, Hongwei Zhang.
J Cancer, 2018 Jun 26; 9(12). PMID: 29937943    Free PMC article.
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Verena Rolfes, Christian Idel, +8 authors, Barbara Wollenberg.
Oncotarget, 2018 Jun 26; 9(44). PMID: 29937998    Free PMC article.
Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Jin-Hua Chen, Jia-Lian Yang, +2 authors, Chin-Chuan Hung.
Sci Rep, 2018 Jun 28; 8(1). PMID: 29946182    Free PMC article.
Combining immunotherapy and radiotherapy in lung cancer.
Neeraj Bhalla, Rachel Brooker, Michael Brada.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951296    Free PMC article.
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara, Sara Pilotto, +7 authors, Emilio Bria.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951307    Free PMC article.
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.
Anshuman Panda, Anil Betigeri, +14 authors, Shridar Ganesan.
JCO Precis Oncol, 2017 Jan 01; 2017. PMID: 29951597    Free PMC article.
Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.
Grant L Lin, Surya Nagaraja, +3 authors, Michelle Monje.
Acta Neuropathol Commun, 2018 Jun 30; 6(1). PMID: 29954445    Free PMC article.
CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols.
Jai Woong Seo, Richard Tavaré, +7 authors, Katherine W Ferrara.
Clin Cancer Res, 2018 Jul 04; 24(20). PMID: 29967252    Free PMC article.
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
Su Yin Lim, Helen Rizos.
Mamm Genome, 2018 Jul 04; 29(11-12). PMID: 29968076    Free PMC article.
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Muhammad Umair Mushtaq, Athanasios Papadas, +4 authors, Fotis Asimakopoulos.
J Immunother Cancer, 2018 Jul 05; 6(1). PMID: 29970158    Free PMC article.
IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.
Bhalchandra Mirlekar, Daniel Michaud, +2 authors, Yuliya Pylayeva-Gupta.
Cancer Immunol Res, 2018 Jul 08; 6(9). PMID: 29980536    Free PMC article.
Standardized Uptake Values Derived from 18F-FDG PET May Predict Lung Cancer Microvessel Density and Expression of KI 67, VEGF, and HIF-1α but Not Expression of Cyclin D1, PCNA, EGFR, PD L1, and p53.
Alexey Surov, Hans Jonas Meyer, Andreas Wienke.
Contrast Media Mol Imaging, 2018 Jul 10; 2018. PMID: 29983647    Free PMC article.
Systematic Review.
A team effort: natural killer cells on the first leg of the tumor immunity relay race.
Timothy B Fessenden, Ellen Duong, Stefani Spranger.
J Immunother Cancer, 2018 Jul 11; 6(1). PMID: 29986768    Free PMC article.
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.
Iris Scherwitzl, Alicia Hurtado, +3 authors, Daniel Meruelo.
Mol Ther Oncolytics, 2018 Jul 11; 9. PMID: 29988525    Free PMC article.
CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer.
Shengbo Zhang, Ming Zhong, +3 authors, Yan Zhang.
Cell Death Dis, 2018 Jul 12; 9(7). PMID: 29991744    Free PMC article.
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.
Jia-Ren Lin, Benjamin Izar, +5 authors, Peter K Sorger.
Elife, 2018 Jul 12; 7. PMID: 29993362    Free PMC article.
Highly Cited.
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Alexander C Hopkins, Mark Yarchoan, +7 authors, Elizabeth M Jaffee.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997287    Free PMC article.
Highly Cited.
CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.
Diane Goltz, Heidrun Gevensleben, +6 authors, Dimo Dietrich.
JCI Insight, 2018 Jul 13; 3(13). PMID: 29997292    Free PMC article.
Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.
Chongkai Wang, Jun Gong, +2 authors, Marwan Fakih.
J Gastrointest Oncol, 2018 Jul 13; 9(3). PMID: 29998005    Free PMC article.
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Kristina Buder-Bakhaya, Jessica C Hassel.
Front Immunol, 2018 Jul 14; 9. PMID: 30002656    Free PMC article.
Highly Cited. Review.
Microbial biomarkers for immune checkpoint blockade therapy against cancer.
Keishi Adachi, Koji Tamada.
J Gastroenterol, 2018 Jul 14; 53(9). PMID: 30003334    Free PMC article.
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.
Lorenzo Pilla, Cristina Maccalli.
Biomedicines, 2018 Jul 14; 6(3). PMID: 30004433    Free PMC article.
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin.
Immunotherapy, 2018 Jul 17; 10(9). PMID: 30008259    Free PMC article.
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Limo Chen, Lixia Diao, +36 authors, Don L Gibbons.
Cancer Discov, 2018 Jul 18; 8(9). PMID: 30012853    Free PMC article.
Highly Cited.
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.
Barbara Castella, Myriam Foglietta, Chiara Riganti, Massimo Massaia.
Front Immunol, 2018 Jul 18; 9. PMID: 30013559    Free PMC article.
The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
Huijie Jia, Wenjing Ren, +10 authors, Zhongwei Tian.
Int J Oncol, 2018 Jul 18; 53(3). PMID: 30015838    Free PMC article.
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Douglas B Johnson, Jennifer Bordeaux, +22 authors, Naveen Dakappagari.
Clin Cancer Res, 2018 Jul 20; 24(21). PMID: 30021908    Free PMC article.
The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
Wu Zhuang, Junxun Ma, +14 authors, Zhijie Wang.
J Cancer, 2018 Jul 22; 9(13). PMID: 30026825    Free PMC article.
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Michael Flynn, Kate Young, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034550    Free PMC article.
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.
H Halse, A J Colebatch, +13 authors, P J Neeson.
Sci Rep, 2018 Jul 26; 8(1). PMID: 30042403    Free PMC article.
Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens.
Giulia Escobar, Luigi Barbarossa, +12 authors, Luigi Naldini.
Nat Commun, 2018 Jul 26; 9(1). PMID: 30042420    Free PMC article.
Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location.
Longhui Zhang, Yuetao Zhao, +6 authors, Bo Zhu.
Front Immunol, 2018 Jul 26; 9. PMID: 30042763    Free PMC article.
Highly Cited.
Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.
Nicolas Jacquelot, Laurence Zitvogel, Alexander M Eggermont.
Nat Commun, 2018 Jul 28; 9(1). PMID: 30050125    Free PMC article.
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060457    Free PMC article.
Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges.
Marco De Simone, Grazisa Rossetti, Massimiliano Pagani.
Front Immunol, 2018 Aug 04; 9. PMID: 30072991    Free PMC article.
Biomarkers for Immune Checkpoint Inhibitors in Melanoma.
Shigehisa Kitano, Takayuki Nakayama, Makiko Yamashita.
Front Oncol, 2018 Aug 04; 8. PMID: 30073150    Free PMC article.
White paper on microbial anti-cancer therapy and prevention.
Neil S Forbes, Robert S Coffin, +20 authors, Grant McFadden.
J Immunother Cancer, 2018 Aug 08; 6(1). PMID: 30081947    Free PMC article.
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Jingjing Duan, Yu Wang, Shunchang Jiao.
Cancer Med, 2018 Aug 09; 7(9). PMID: 30088347    Free PMC article.
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Gang Chen, Alexander C Huang, +36 authors, Wei Guo.
Nature, 2018 Aug 10; 560(7718). PMID: 30089911    Free PMC article.
Highly Cited.
Next Generation Cancer Vaccines-Make It Personal!
Angelika Terbuch, Juanita Lopez.
Vaccines (Basel), 2018 Aug 12; 6(3). PMID: 30096953    Free PMC article.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
S N Gettinger, J Choi, +19 authors, K A Schalper.
Nat Commun, 2018 Aug 12; 9(1). PMID: 30097571    Free PMC article.
Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
Nausicaa Malissen, Jean-Jacques Grob.
Drugs, 2018 Aug 12; 78(12). PMID: 30097888
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Sarwish Rafiq, Oladapo O Yeku, +14 authors, Renier J Brentjens.
Nat Biotechnol, 2018 Aug 14; 36(9). PMID: 30102295